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HIGHLIGHTS 22 
 Interaction of NCL with G4 of EBNA1 mRNA is involved into immune evasion of EBNA1 and EBV 23 
 Cationic bis(acylhydrazones) were developed as novel ligands binding to G4 of EBNA1 mRNA 24 
 SAR of novel ligands with respect to in vitro binding to G4 of EBNA1 mRNA is discussed 25 
 Two novel ligands enhance the expression of EBNA1 and antigen presentation 26 
 Novel ligands disrupt the NCL–EBNA1 mRNA interaction in cellulo as shown by PLA  27 
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ABSTRACT 1 
The oncogenic Epstein–Barr virus (EBV) evades the immune system through limiting the expression of 2 
its highly antigenic and essential genome maintenance protein, EBNA1, to the minimal level to ensure 3 
viral genome replication, thereby also minimizing the production of EBNA1-derived antigenic peptides. 4 
This regulation is based on inhibition of translation of the virally-encoded EBNA1 mRNA, and involves 5 
the interaction of host protein nucleolin (NCL) with G-quadruplex (G4) structures that form in the 6 
glycine–alanine repeat (GAr)-encoding sequence of the EBNA1 mRNA. Ligands that bind to these G4-7 
RNA can prevent their interaction with NCL, leading to disinhibition of EBNA1 expression and antigen 8 
presentation, thereby interfering with the immune evasion of EBNA1 and therefore of EBV (M. Lista et 9 
al., Nature Commun., 2017, 8, 16043). In this work, we synthesized and studied a series of 20 cationic 10 
bis(acylhydrazone) derivatives designed as G4 ligands. The in vitro evaluation showed that most 11 
derivatives based on central pyridine (Py), naphthyridine (Naph) or phenanthroline (Phen) units were 12 
efficient G4 binders, in contrast to their pyrimidine (Pym) counterparts, which were poor G4 binders 13 
due a significantly different molecular geometry. The influence of lateral heterocyclic units (N-14 
substituted pyridinium or quinolinium residues) on G4-binding properties was also investigated. Two 15 
novel compounds, namely PyDH2 and PhenDH2, when used at a 5 µM concentration, were able to 16 
significantly enhance EBNA1 expression in H1299 cells in a GAr-dependent manner, while being 17 
significantly less toxic than the prototype drug PhenDC3 (GI50 > 50 µM). Antigen presentation, RNA 18 
pull-down and proximity ligation assays confirmed that the effect of both drugs was related to the 19 
disruption of NCL–EBNA1 mRNA interaction and the subsequent promotion of GAr-restricted antigen 20 
presentation. Our work provides a novel modular scaffold for the development of G-quadruplex-21 
targeting drugs acting through interference with G4-protein interaction. 22 
 23 
KEYWORDS 24 
Epstein–Barr virus • G-quadruplex RNA • G-quadruplex ligands • Nucleolin • Immune evasion  25 
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1. INTRODUCTION 1 
The Epstein–Barr virus (EBV) is the first oncogenic virus discovered in human. Most of world’s adult 2 
population (>90%) is infected with the virus but do not develop any pathology [1]. However, a small 3 
proportion of infected individuals develops EBV-linked cancers, which include Burkitt and Hodgkin 4 
lymphomas, and up to 10% gastric carcinomas, as well as nasopharyngeal carcinoma, particularly 5 
frequent among men in China and Tunisia [1,2]. Like all gamma-herpesviruses, EBV effectively evades 6 
the host immune system but has an Achilles heel, namely its genome maintenance protein EBNA1. 7 
EBNA1 is essential for EBV genome replication and maintenance and, as such, is expressed in all 8 
dividing EBV-infected cells. On the other hand, EBNA1 is highly antigenic, and CD8+ T cells directed 9 
towards EBNA1 epitopes are present in all infected individuals. Hence, EBV has seemingly evolved a 10 
mechanism to limit EBNA1 production to the minimal level required for the viral genome replication 11 
thereby, at the same time, minimizing the production of EBNA1-derived antigenic peptides presented 12 
to the cytotoxic T cells through the major histocompatibility complex (MHC) class I pathway. The 13 
central glycine–alanine repeat (GAr) of EBNA1 plays a critical role in this mechanism of immune 14 
evasion, as it is able to self-inhibit the translation of its own mRNA in cis. Remarkably, infection by an 15 
EBV strain encoding a truncated version of EBNA1 in which GAr has been deleted (EBNA1ΔGAr) leads 16 
to high level of EBNA1 protein and to an efficient T cell response, which demonstrates the critical role 17 
of GAr in EBNA1 immune evasion [3]. GAr-based EBNA1 immune evasion is considered a relevant 18 
therapeutic target in the treatment of EBV-related cancers, since most tumor cells from these cancers 19 
are infected by EBV whereas, in healthy individuals, the latent infection by EBV is primarily restricted 20 
to a specific small pool of memory B cells. Hence, overcoming the GAr-based self-inhibition of EBNA1 21 
translation should unveil EBV-carrying tumor cells to cytotoxic T cells without having significant effect 22 
on the vast majority of healthy host cells. Of note, GAr is polymorphic with respect to its length and, 23 
importantly, the effect of GAr is length-dependent: longer domains display a stronger inhibitory effect 24 
on both mRNA translation and antigen presentation [4–6]. 25 
The GAr-encoding mRNA sequence is GC-rich and is capable of forming multiple G-quadruplex (G4) 26 
structures, which were shown to be implicated in the regulation of EBNA1 synthesis in vitro [7]. G4s 27 
are particular secondary structures of nucleic acids formed through the stacking of G-quartets, that is, 28 
planar arrangements of four guanines connected by Hoogsteen hydrogen bonds. G4 structures within 29 
G-rich DNA or RNA sequences have been implicated in gene regulation where they can affect 30 
transcription, splicing and translation [8,9]. The mechanisms of G4-based regulation are still poorly 31 
understood, but cellular factors that interact with these structures are rapidly emerging [10,11]. 32 
Moreover, an increasing number of pathologies, that include cancer, neurodegenerative disorders, 33 
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bacterial and viral diseases, have been associated with G4-based regulation, illustrating the potential 1 
importance of these structures as therapeutic targets [12–17]. 2 
Along these lines, we have previously developed a yeast (Saccharomyces cerevisiae)-based  assay 3 
reproducing all the aspects of the GAr-based inhibition of translation, including the GAr-length 4 
dependency [18]. This allowed us to decipher the mechanisms of GAr-mediated mRNA translation 5 
suppression in cis and, in particular, to identify the cellular factors involved [19,20]. The yeast assay 6 
was successfully used first to identify small molecular-weight compounds that can stimulate EBNA1 7 
expression both in yeast and in mammalian cells and relieve the GAr-based limitation of antigen 8 
presentation [18,20]. More recently, this model was employed for a genetic screen that aimed at 9 
identifying host cell genes involved in the GAr-mediated inhibition of translation. This enabled us to 10 
identify the yeast NSR1 gene encoding the ortholog of human nucleolin (NCL) [21], and to demonstrate 11 
that NCL is critically involved in the GAr-based limitation of EBNA1 translation and antigen 12 
presentation, and thus in the immune evasion of EBV. Specifically, we showed that NCL directly 13 
interacts in the nucleus (or in close vicinity of the nucleus) with G4s that form in the GAr-encoding 14 
sequence of EBNA1 mRNA and inhibits its translation, thereby limiting the production of EBNA1-15 
derived antigenic peptides which, in turn, favors immune evasion of EBV-infected cells [22]. 16 
Consequently, the interaction of NCL with G4 of EBNA1 mRNA appears a relevant therapeutic target 17 
for the treatment and/or prevention of EBV-related cancers, as drugs that disrupt this interaction 18 
could, in principle, overcome the GAr-based EBNA1 immune evasion of EBV. In line, we demonstrated 19 
that the benchmark G4 ligand PhenDC3 is able to prevent NCL from binding to G4s formed in the GAr 20 
mRNA sequence, and to stimulate GAr-limited translation and antigen presentation (Fig. 1a) [22].  21 
Importantly, this ability of PhenDC3 is not a general property of all the G4-ligands since the other 22 
benchmark G4 ligand, pyridostatine (PDS), has no effect on NCL binding nor on GAr-based inhibition 23 
of translation. Hence, it appears that active G4 ligands not only need to bind efficiently to G4 that form 24 
in the GAr-encoding sequence of EBNA1 mRNA, but they should also be able to interfere with NCL 25 
binding, which does not appear as a general property of all G4 ligands. 26 
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 1 
Fig. 1. a) Effect of G-quadruplex ligands on the nucleolin (NCL)- and GAr-dependent limitation of EBNA1 synthesis. 2 
NCL binds directly to G-quadruplexes (G4s) formed in the GAr-encoding sequence of EBNA1 mRNA, thus 3 
inhibiting its translation and thereby leading to a weak production of EBNA1 protein and EBNA1-derived 4 
antigenic peptides. This allows EBNA1 and EBV to evade the immune system. Some G4 ligands like PhenDC3 5 
compete with NCL for binding to G4s of EBNA1 mRNA, thereby relieving the inhibitory effect of GAr and NCL on 6 
both translation and antigen presentation. b) Design of cationic bis(acylhydrazone) ligands featuring shape 7 
similarity to PhenDC3. 8 
With the aim to explore new pharmaceutical scaffolds as putative G4 ligands and disruptors of the 9 
NCL–EBNA1 G4-mRNA interactions, we designed a series of cationic bis(acylhydrazone) derivatives 10 
representing shape analogues of PhenDC3 (Fig. 1b). These U-shaped scaffolds are expected to provide 11 
an optimal overlap with G-tetrads, as demonstrated by the structural model of PhenDC3 bound to a 12 
parallel-stranded G4-DNA substrate [23]. In addition, the N-acylhydrazone group has been identified 13 
as a privileged scaffold in drug design, due to a combination of hydrogen-bond acceptor and donor 14 
sites capable of interactions with a wide range of biomolecules. Despite the fact that acylhydrazone 15 
derivatives are rapidly metabolized, this motif is encountered in several approved drugs (e.g., 16 
nifuroxazide and dantrolene) [24] and drug candidates [25–27]. The facile synthetic availability of 17 
acylhydrazone derivatives, which allows furnishing congeneric series of compounds with distinct 18 
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physico-chemical properties and bioactivities, makes it a promising scaffold in the drug discovery field 1 
[28–30]. Herein, we describe the synthesis of novel derivatives and the determination of their in vitro 2 
and in cellulo ability to bind to G4 of EBNA1 mRNA, as well as their effect on NCL-mediated GAr-3 
dependent limitation of EBNA1 expression and antigen presentation. 4 
2. RESULTS 5 
2.1. Chemistry 6 
The design of cationic bis(acylhydrazones) features a central heterocyclic core Ar1, i.e., a derivative of 7 
pyridine (Py), pyrimidine (Pym), 1,8-naphthyridine (Naph), or 1,10-phenanthroline (Phen), connected 8 
via two acyhydrazone linkages to lateral, N-substituted cationic heterocycles (Ar2 = pyridinium or 9 
quinolinium, R = Me, Et, or Bn). Our initial approach to the synthesis of these derivatives relied on the 10 
formation of neutral bis(acylhydrazone) precursors, followed by quaternization of lateral heterocyclic 11 
residues (Scheme 1, path A). Thus, four heterocyclic bis(acylhydrazides) 1–4, obtained by a 12 
hydrazinolysis of the corresponding dimethyl esters, were made to react with three heteroaromatic 13 
aldehydes 5a–c, to give the 11 corresponding bis(acylhydrazones) 6a–c, 7a–c, 8a–c and 9a–c, with 14 
yields ranging from 55 to 99% (Experimental Part). Subsequent quaternization using excess alkyl or 15 
benzyl halide gave the corresponding cationic bis(acylhydrazones). However, while some products 16 
(e.g., PyDH1, PyDH2) could be obtained in a pure form after a single recrystallization, several other 17 
ones (e.g., PymDH1, PymDH2, NaphDH2) contained up to 20% (as per 1H NMR) of mono-alkylated 18 
product as an impurity, which could not be removed even after repeated recrystallizations. Therefore, 19 
we elaborated an alternative synthesis of these derivatives (Scheme 1, path B), relying on N-alkylation 20 
of heteroaromatic aldehydes in a first step, and obtained five quaternized aldehydes (10a, 11a–b, 12a–21 
b) isolated as stable, but hygroscopic salts in good yields (73–94%). The subsequent condensation of 22 
the latter with bis(acylhydrazides) 1–4 gave a series of 20 cationic bis(acylhydrazones) (PyDH1–5, 23 
PymDH1–5, NaphDH1–5, and PhenDH1–5, Table 1), all obtained as iodide or bromide salts in good 24 
yields (50–97%) and excellent purity after a single recrystallization. The identity and purity of all final 25 
compounds were confirmed using spectroscopic and chromatographic methods and combustion 26 
analysis.  27 
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 2 
Scheme 1. Synthesis of cationic bis(acylhydrazones). Reagents and conditions: (i) N2H4×H2O, EtOH, reflux, 18 h; 3 
(ii) EtOH, reflux, 18 h; (iii) RX, DMF, 40 °C or 60 °C, 18 h; (iv) RX, DCM, r.t., 72 h or acetone, reflux, 18 h; (v) DMF, 4 
80 °C or 100 °C, 2 h. 5 
Table 1. Structures of novel cationic bis(acylhydrazones) 6 
                Ar2 
 
      Ar1 
 
 
 
 
 
 
PyDH1 PyDH2 PyDH3 PyDH4 PyDH5 
 
PymDH1 PymDH2 PymDH3 PymDH4 PymDH5 
 
NaphDH1 NaphDH2 NaphDH3 NaphDH4 NaphDH5 
 
PhenDH1 PhenDH2 PhenDH3 PhenDH4 PhenDH5 
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 1 
2.2. Structural characterization 2 
X-ray quality crystals of PyDH1 (2I–), PymDH1 (2I–), and PhenDH1 (2I–) could be obtained from 3 
acetonitrile–water (in the case of PymDH1 (2I–), a simultaneous formation of yellow and orange 4 
polymorphs was observed, both belonging to the P1͞ space group but differing by the packing of 5 
cations). Single-crystal diffraction analysis revealed that in all three compounds the organic cations 6 
were essentially planar, with minimal twisting at the level of terminal heterocyclic rings breaking the 7 
two-fold molecular symmetry (Fig. 2). In all cases, both N-acylhydrazone groups adopted E–8 
antiperiplanar conformation. Remarkably, PyDH1 and PhenDH1 revealed co-crystallized water 9 
molecules located in between the two acylhydrazone groups and forming hydrogen bonds with both 10 
amide NH groups (PyDH1: d(NH∙∙∙O) = 2.84 and 2.90 Å, α(N-H∙∙∙O) = 150°; PhenDH1: d(NH∙∙∙O) = 2.85 11 
and 2.84 Å, α(N-H∙∙∙O) ≈ 170°). In addition, in PyDH1 the water molecule formed a weak hydrogen 12 
bond with the pyridine nitrogen (d(N∙∙∙O) = 3.08 Å, Fig. 2, a), whereas in PhenDH1 it formed a stronger, 13 
bifurcated hydrogen bonds with both phenanthroline nitrogens (mean d(N∙∙∙O) = 2.95 Å, Fig. 2c). The 14 
coordination of water molecules thus determines the inward-folded, V-shaped conformation of 15 
PyDH1, similar to what was observed with related, charge-neutral pyridine-2,6-bis(acylhydrazones) 16 
[31], as well as the U-shaped conformation of PhenDH1 which is further stabilized due to the number 17 
and favorable arrangement of hydrogen bonds. In contrast, PymDH1 (Fig. 2b) was found to adopt a 18 
linear conformation, partially stabilized by intramolecular bonds between the amide NH groups and 19 
nitrogen atoms of the pyrimidine core (d(N∙∙∙N) = 2.66 Å). Although this compound also crystallized 20 
along with water molecules, the latter were found to coordinate to amide CO groups, on one hand, 21 
and iodide anions, on the other hand (not shown). 22 
It may be suggested that the described interactions with water molecules persist in aqueous solutions, 23 
governing the molecular shape of bis(acylhydrazone) ligands. In this context, V- or U-shaped 24 
derivatives PyDHn and PhenDHn, presumably, have a more favorable structure for binding to G4-25 
quadruplex structures due to a more complete overlap with G-tetrads, as compared to linear 26 
analogues PymDHn. 27 
 28 
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 1 
Fig. 2. Solid-state structures of a) PyDH1 (2I–) × 2 H2O, b) PymDH1 (2I–) × 2 H2O × MeCN (yellow form), and c) 2 
PhenDH1 (2I–) × 2 H2O × MeCN, from single-crystal X-ray diffraction analysis. Non-bound water, acetonitrile 3 
molecules and counter-ions were omitted for clarity. CPK atom colors; green lines and labels indicate 4 
intermolecular hydrogen bonds with crystallized water molecules and the corresponding N∙∙∙O distances. 5 
2.3. In silico evaluation 6 
The drug-like properties of cationic bis(acylhydrazones) were evaluated using SwissADME, a free tool 7 
allowing to assess the physicochemical descriptors, pharmacokinetics (ADME), and drug-likeness of 8 
small molecules [32]. It should be noted that certain methods of in silico evaluation are poorly suitable 9 
for cationic compounds as the ones described in this work, as illustrated by significant variance of 10 
physico-chemical properties predicted by different algorithms for the same compound (e.g. for PyDH1, 11 
cLogP from –7.75 to 1.83, Table S1). According to the established practices, consensus estimation (i.e., 12 
the average of five models) was used in evaluation of drug-likeness of compounds [32]. The results of 13 
in silico assessment (Fig. S1 and Table S1) indicated satisfactory bioavailability for most 14 
bis(acylhydrazones), as given by the combination of six physicochemical descriptors (lipophilicity, 15 
molecular weight, polarity, solubility, saturation and number of rotatable bonds). Among those, 16 
insufficient saturation (i.e., low fraction of sp3 carbons) could be identified as the limiting factor for 17 
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bioavailability of most derivatives, as well as high molecular weight for the derivatives NaphDH3, 1 
NaphDH5, PhenDH3 and PhenDH5 (M > 700 Da). With the exception of the latter four derivatives, all 2 
bis(acylhydrazones) satisfied the Lipinski’s rule, and most derivatives also satisfied the Muegge’s rule 3 
[33], indicating a high potential to serve as drugs (Table S1). Finally, we employed a gastrointestinal 4 
absorption predictor calculated by the BOILED-egg model (Fig. 3) [34]. According to this model, most 5 
compounds, again with the exception of NaphDH3, NaphDH5, and PhenDH3–5, had a high rate of 6 
passive gastrointestinal absorption; however, none of compounds was expected to cross the blood-7 
brain barrier (Fig. 3). In conclusion, the results of in silico evaluation indicate that the cationic 8 
bis(acylhydrazone) scaffolds are compatible with their use as RNA-targeting drugs, while heavy and 9 
aromatic substitutes (e.g., R = Bn) should be avoided for the sake of bioavailability, unless 10 
indispensable for RNA binding. 11 
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Fig. 3. BOILED-egg evaluation [34] of passive gastrointestinal absorption (HIA) and brain (BBB) penetration of 13 
bis(acylhydrazones). The white region indicates high probability of passive gastrointestinal absorption, and the 14 
yellow region indicates high probability of BBB penetration. 15 
The compounds were also assessed for the presence of fragments associated with pan-assay 16 
interfering compounds (PAINS). The presence of quinolinium fragments was identified as potentially 17 
troublesome in some (but not all) compounds (Table S1); however, an inspection of the original screen 18 
revealed that this fragment was mainly associated with cationic dyes, potentially interfering with 19 
colorimetric or fluorimetric assays [35]. Since bis(acyhydrazones) are colorless or faintly colored 20 
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compounds, this filter was not applied and all compounds were systematically assessed by biophysical 1 
and biological tests. 2 
2.4. Biophysical studies of interaction of novel ligands with G4 of EBNA1 mRNA and G4-DNA 3 
The interaction of novel bis(acylhydrazone) derivatives with the most frequent G4-forming motif 4 
encountered in GAr-encoding sequence of the EBNA1 mRNA (g4-EBNA1, 5′-r(GGGGCAGGA-5 
GCAGGAGGA)-3′) was studied in vitro using two widely established methods, namely fluorescence-6 
monitored thermal denaturation (fluorescence melting) and fluorescent indicator displacement (FID) 7 
assay. In the first method, the binding of ligands is manifested by an increase of denaturation 8 
temperature (∆Tm) of oligoribonucleotide F-g4-EBNA1-T, bearing a fluorophore (5′, 6-FAM) and a 9 
quencher (3′, TAMRA). In our conditions (10 mM KAsO2Me2, 10 mM KCl, 90 mM LiCl buffer, pH 7.3) 10 
and in the absence of ligands, F-g4-EBNA1-T denatured at Tm0 = 58.6 °C, which is slightly higher than 11 
the reported value (54 °C) [7]. In addition to the ranking of ligands with respect to their ability to 12 
stabilize the G4 substrate, fluorescence melting experiments provide information on G4-RNA vs. ds-13 
DNA selectivity of ligands, namely through analysis of the drop of ∆Tm values observed in the presence 14 
of unlabeled, double-stranded DNA competitor (ds26, 15 or 50 molar equivalents) [36]. The results 15 
(Fig. 4, a) demonstrate that bis(acylhydrazone) derivatives display great variability with respect to their 16 
capacity to bind to and stabilize g4-EBNA1, revealing interesting structure–activity relationships 17 
discussed in details below. Specifically, most derivatives of the PyDH and NaphDH families, as well as 18 
PhenDH1, demonstrated significant stabilization of g4-EBNA1 (∆Tm = 10 to 20 °C), and further 19 
phenanthroline derivatives (PhenDH2–5) demonstrated even higher stabilization of the substrate (∆Tm 20 
= 20 to 30 °C), comparable to the result obtained with PhenDC3 (∆Tm = 30.0 °C). In contrast, all 21 
derivatives of the PymDH family, as well as compounds PyDH1 and NaphDH1, demonstrated low or 22 
very low stabilization of G4-RNA (∆Tm < 10 °C), illustrating the importance of the nature of heterocyclic 23 
residues on the G4-RNA binding properties of ligands. Finally, most derivatives that stabilized g4-24 
EBNA1 also displayed significant level of selectivity with respect to ds-DNA, as their stabilizing effect 25 
was almost unaffected by the presence of ds-DNA competitor. 26 
To assess the selectivity of novel ligands for G4 of EBNA1 mRNA, additional fluorescence melting 27 
experiments were performed with two G4-DNA substrates, namely F-24TTG-T (predominantly a 28 
hybrid-1 G4 structure, adopted by a variant of human telomeric DNA sequence) [37] and F-myc22-T 29 
(parallel-stranded G4-DNA, adopted by variant of the G4-forming sequence from the promoter region 30 
of c-Myc oncogene) [38]. The results (Fig. S2) demonstrate no preferential stabilization of one or 31 
another substrate, since all compounds that stabilized g4-EBNA1 (PyDH2–5, NaphDH2–5, and all 32 
PhenDH derivatives) also strongly stabilized both G4-DNA substrates (with ∆Tm = 15 to 30 °C). A similar 33 
behavior was observed with PhenDC3, which stabilized both G4-DNA with ∆Tm of over 35 °C. The lack 34 
12 
 
of selectivity is not surprising given the structural similarity of novel ligands to PhenDC3 (a polyvalent 1 
G4 binder) and indicates a similar binding mode, relying on compound stacking with terminal G-tetrads 2 
of G4 structures. Obviously, the substituents explored in this work (ethyl or phenyl groups) are not 3 
sufficient for achieving a significant level of selectivity between different G4 structures. 4 
0
5
10
15
20
25
30
L
ig
a
n
d
-i
n
d
u
c
e
d
 s
ta
b
ili
z
a
ti
o
n
 ∆
T
m
 (
°C
) PyDHn PymDHn NaphDHn PhenDHn
a)
 5 
P
yD
H
1
P
yD
H
2
P
yD
H
3
P
yD
H
4
P
yD
H
5
P
ym
D
H
1
P
ym
D
H
2
P
ym
D
H
3
P
ym
D
H
4
P
ym
D
H
5
N
ap
hD
H
1
N
ap
hD
H
2
N
ap
hD
H
3
N
ap
hD
H
4
N
ap
hD
H
5
P
he
nD
H
1
P
he
nD
H
2
P
he
nD
H
3
P
he
nD
H
4
P
he
nD
H
5
P
he
nD
C
3
1
2
3
4
5
6
1
 /
 D
C
5
0
 (
µ
M
-1
)
b)
n
.d
.
n
.d
.
n
.d
.
 6 
Fig. 4. In vitro binding of tested compounds to g4-EBNA1. a) Thermal stabilization F-g4-EBNA1-T (0.2 µM) by 7 
tested compounds (1.0 µM), assessed by fluorescence melting experiments in the absence (dark red bars) or in 8 
the presence of duplex DNA competitor ds26 (red bards: 3 µM, pale red bars: 10 µM). The experiments were 9 
performed in K10 buffer (10 mM LiAsO2Me2, 10 mM KCl, 90 mM LiCl, pH 7.3); data are means ± s.d. from three 10 
technical replicates. b) Ligand-induced displacement of TO (0.5 µM) from g4-EBNA1 (0.25 µM). Data are means 11 
± s.d. from three technical replicates; n.d. = no displacement (DC50 > 2.5 µM). The experiments were performed 12 
in K100 buffer (10 mM LiAsO2Me2, 100 mM KCl, 1 mM EDTA, 1% v/v DMSO). 13 
A complementary information about ligand affinity for g4-EBNA1 was obtained from the FID assay, 14 
which assesses the binding of ligands through displacement of a fluorescent probe (Thiazole Orange, 15 
TO). In this assay, the apparent ligand affinity is given by the concentration required to displace 50% 16 
of the bound probe (DC50) [39]. The results of the FID assay (Fig. 4b and Table S2) indicated high g4-17 
EBNA1 affinity (DC50 < 0.5 µM) for compounds PyDH2, PyDH3, as well as PhenDH1–3, which was 18 
13 
 
comparable to the result obtained for PhenDC3 (DC50 = 0.31 µM). In contrast, the derivatives PyDH1, 1 
PymDH1, PymDH4 and PyDH5 were not able to displace TO from g4-EBNA1 (DC50 > 2 µM), giving 2 
evidence of low affinity, whereas other derivatives demonstrated moderate affinity (DC50 = 0.5 to 3 
2 µM). Of note, none of tested ligands was able to induce displacement of TO from the double-4 
stranded DNA substrate ds26 (DC50 > 2.5 µM in all cases). Globally, the results obtained with both 5 
biophysical methods were in a good agreement, except for a few discrepancies (compounds PyDH5, 6 
NaphDH2–5 and PhenDH4–5 which demonstrated high thermal stabilization of g4-EBNA but only 7 
moderate capacity to displace TO, DC50 = 0.5 to 1 µM). Altogether, the results of biophysical studies 8 
point to pyridine derivatives PyDH2 and PyDH3, as well as all derivatives of the phenanthroline series, 9 
as most promising ligands for g4-EBNA. 10 
2.5. Biological tests 11 
2.5.1. Effect of compounds on GAr-dependent protein expression 12 
To assay the biological activity of the various compounds bis(acylhydrazones), we first determined 13 
their effect on the GAr-dependent limitation of EBNA1 expression, which represents a mechanism at 14 
the basis of EBNA1/EBV immune evasion. For this purpose, human lung carcinoma H1299 cells were 15 
transfected with EBNA1 or EBNA1ΔGAr constructs and treated with 10 µM of the indicated compounds 16 
or, as a control, with DMSO (the vehicle). Then, the levels of EBNA1 or EBNA1ΔGAr was assessed by 17 
western blot analysis using an antibody raised against EBNA1 and, as a loading control, an antibody 18 
raised against GAPDH. PhenDC3 was used as a positive control and DMSO as a negative control. In this 19 
assay, three types of results were observed (Table 2): (i) most of the compounds had no effect 20 
(indicated by a “0”); (ii) two compounds, namely PyDH2 and PhenDH2, similarly to PhenDC3, led to a 21 
GAr-dependent increase in EBNA1 expression, indicated by a “+” (i.e., they increased EBNA1 level while 22 
having no effect on EBNA1ΔGAr); and finally (iii) three compounds (PyDH3, PymDH5, and PhenDH1) 23 
increased EBNA1 level in a GAr-independent manner indicated by a “×” (i.e., they increased both 24 
EBNA1 and EBNA1ΔGAr levels). The western blot results obtained with compounds PyDH2 and 25 
PhenDH2 are presented on Fig. 5a. As we were interested in compounds able to interfere with the 26 
GAr-dependent limitation of EBNA1 expression and antigen presentation, a mechanism at the basis of 27 
EBNA1 immune evasion, we focused only on the compounds that increase EBNA1 level while having 28 
no effect on EBNA1ΔGAr, namely PhenDH2 and PyDH2. 29 
Table 2. Effect of compounds (all tested at 5 µM) on EBNA1 expression in H1299 cells. 30 
Compound Effecta Compound Effecta Compound Effecta Compound Effecta 
PyDH1 0 (106/93)b PymDH1 0 (80/92)b NaphDH1 0 (112/99)b PhenDH1 × (78/76)b,c 
PyDH2 + (162/101)b PymDH2 0 (89/103)b NaphDH2 0 (95/100)b PhenDH2 + (189/96)b 
14 
 
PyDH3 × (134/149)b PymDH3 0 (108/106)b NaphDH3 0 (106/93)b PhenDH3 0 (96/114)b 
PyDH4 0 (86/98)b PymDH4 × (48/47)b,c NaphDH4 0 (82/111)b PhenDH4 0 (80/96)b 
PyDH5 × (58/70)b,c PymDH5 ×(139/137)b NaphDH5 0 (104/108)b PhenDH5 0 (111/94)b 
a 0: No effect ; +: GAr-dependent increase in EBNA1 expression; ×: GAr-independent effect. b Number between 1 
brackets indicate the quantification of respectively GAr-OVA (numerator) and OVA (denominator) levels, as 2 
compared to their respective levels in DMSO-treated cells. c Values in italics, which are significantly smaller than 3 
100, point to compounds that are toxic to both GAr-OVA- and OVA-expressing cells. 4 
 5 
Fig. 5. a) Expression of EBNA1 (top panel) or EBNA1∆GAr (bottom panel) in transfected H1299 cells treated with 6 
DMSO (control), PyDH2 (10 µM), or PhenDH2 (10 µM) 40 h post-transfection. b) Expression of 235GAr-OVA (top 7 
panel) or OVA (bottom panel) in transfected H1299 cells treated with DMSO (control), PhenDC3, PyDH2, or 8 
PhenDH2 (all at 10 µM) 40 h post-transfection. c) Expression of 235GAr-OVA or OVA in transfected H1299 cells 9 
treated with PyDH2 used at 0 (control), 7.5, 10, or 15 µM concentration. Protein (EBNA1, EBNA1∆GAr, 235GAr-10 
5 5 5
97
64
51
39
39
39
235GAr-OVA
OVA/GAPDH
OVA
GAPDH
GAPDH
GAr-OVA/GAPDH100 133 182 190
100 107 91 111
(µM)
b)
c)
a)
15 
 
OVA or OVA) levels were normalized with respect to GAPDH (loading control) and the resulting values indicated 1 
below the gels. 2 
On the basis of the compounds effect on the expression of EBNA1 and in silico evaluation of their drug-3 
likeness, PyDH2 and PhenDH2 were selected for further biological studies that include antigen 4 
presentation assay and proximity ligation assay (PLA). For this purpose, we first evaluated the effect 5 
of various concentrations of both compounds on expression of ovalbumin (OVA) and 235GAr-OVA in 6 
H1299 cells using the same procedure as described above for EBNA1. The OVA/235GAr-OVA system 7 
allows to assess the ability of GAr to limit both protein expression and antigen presentation since 8 
235GAr (a full-length, 235 amino-acid GAr domain), when fused to OVA, strongly limits both its 9 
expression and its antigen presentation by the MHC class I pathway. In this way, this model 10 
recapitulates the effect of GAr on EBNA1 expression and antigen presentation [18]. Similar to what has 11 
been observed with PhenDC3 [22], compounds PyDH2 and PhenDH2 increased 235GAr-OVA level in a 12 
dose-dependent manner, whereas having no significant effect on OVA expression (Fig. 5b,c). Together 13 
with the data on the effect of compounds on EBNA1 expression, these results confirm the suggested 14 
mechanism of biological activity of both compounds, namely, relieving of the GAr-dependent inhibition 15 
of protein expression. 16 
2.5.2 Antigen presentation assay 17 
We subsequently studied the ability of compounds PyDH2 and PhenDH2 to interfere with immune 18 
evasion of EBV, via the assessment of the GAr-dependent suppression of antigen presentation. For this 19 
purpose, H1299 cells were transfected with murine MHC class I Kb and 235GAr-OVA or OVA plasmid 20 
constructs and  co-cultured with naive OVA257–264 (SL8 peptide)-specific CD8+ T-cells from OT-1 mice. 21 
Since IL-2 is a potent growth factor stimulating T-cell proliferation, the levels of antigen presentation 22 
were determined by measuring the release of IL-2 in the supernatant by ELISA. IL-2 release following 23 
the treatment of cells with compounds PyDH2 or PhenDH2, as compared to DMSO-treated cells (Fig. 24 
6). These data indicate that PyDH2 used at a concentration of 10 µM, as well as PhenDH2 used at a 25 
concentration of 5 or 10 µM significantly increased the presentation of antigenic peptides from GAr-26 
OVA (more than a two-fold increase), while having no effect on cells expressing OVA. Thus, both 27 
compounds increased antigen presentation levels in a GAr-dependent manner, demonstrating their 28 
ability to significantly interfere with the immune evasion of EBNA1. 29 
16 
 
 1 
Fig. 6. IL2 concentration (pg mL–1) determined following the treatment of H1299 cells expressing OVA (left) or 2 
GAr-OVA (right) with a) DMSO (control), 5 µM and 10 µM of PyDH2; b) DMSO (control), 5 µM and 10 µM of 3 
PhenDH2. *, p < 0.05; ***, p < 0.001; ns, not significant. 4 
2.5.3. Cell viability 5 
The toxicity of compounds PyDH2 and PhenDH2 for Mutu‐1 (Epstein-Barr virus-related Burkitt 6 
lymphoma) cells in a concentration range of 0.5 to 100 µM was assessed using the classical MTT assay 7 
and compared to the result obtained with cells treated by DMSO (compound vehicle). Upon 24 h 8 
treatment, both compounds displayed a relatively low toxicity for Mutu-1 cells (PyDH2: GI50 > 100 µM, 9 
PhenDH2: 50 < GI50 < 100 µM, Fig. 7). Moreover, the toxicity of both compounds was only slightly 10 
higher upon 48 h treatment (PyDH2: GI50 ≥ 100 µM, PhenDH2: GI50 ≈ 20 µM, cf. Supporting 11 
Information, Fig. S3). Thus, both compounds are not significantly toxic when used at a concentration 12 
range in which they increase the expression of EBNA1 and the production of EBNA1-derived antigenic 13 
peptides (i.e., 5–10 µM), in contrast to the prototype drug PhenDC3, which induced significant toxicity 14 
when used at concentrations > 2.5 µM in identical conditions [22]. Thus, as compared to the prototype 15 
G4 ligand PhenDC3, these novel acylhydrazone ligands present the advantage of being significantly 16 
less toxic.  17 
a) b)
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 1 
Fig. 7. Viability (%) of Mutu-1 cells assessed after a 24 h treatment with DMSO (control) or various concentrations 2 
of a) PyDH2 or b) PhenDH2. *, p < 0.05; ***, p < 0.001; ns, not significant. 3 
2.5.4. Inhibition of NCL binding to G4 in EBNA1 mRNA: proximity ligation assay (PLA) and RNA pull-4 
down assay 5 
We employed the proximity ligation assay (PLA) [40] to verify that compounds PyDH2 and PhenDH2 6 
prevent nucleolin (NCL) to interact with the G4s of the GAr-encoding sequence of EBNA1 mRNA, the 7 
mechanism at the basis of the GAr-dependent limitation of EBNA1 expression and antigen 8 
presentation. Briefly, PLA is a technique originally developed to detect proteins in close proximity 9 
(theoretically, at a maximum distance of 40 nm) and which is based on the use of a pair of antibodies 10 
raised in two different species, each targeting one of the two protein of interest. By using labelled 11 
oligomers, PLA has been adapted to the study of protein–DNA [41] and protein–RNA  interactions. In 12 
the latter case, mRNA of interest (i.e., EBNA1) is tagged through in situ hybridization with a digoxigenin-13 
labelled DNA probe, followed by incubation with a mouse anti-digoxigenin, whereas NCL is tagged with 14 
rabbit anti-nucleolin. If both are located in a close proximity, the subsequent incubation with DNA 15 
probe-conjugated anti-rabbit (plus probe) and anti-mouse (minus probe) antibodies and two 16 
connector oligonucleotide probes induces rolling circle amplification, as schematically shown on Fig. 17 
S4 (Supporting Information). The latter generates a concatemeric DNA product, which is finally 18 
detected thorough hybridization with a fluorescently labelled oligonucleotide probe as a distinct bright 19 
spot on a micrograph [42]. This way, we previously demonstrated that NCL interacts with G-20 
quadruplexes formed in the GAr-encoding sequence of EBNA1 mRNA, and that PhenDC3 inhibits this 21 
interaction in Mutu-1 cells as well as in H1299 cells transiently expressing EBNA1 [22,42]. Herein, we 22 
first exploited H1299 cells transiently expressing EBNA1 following transfection with EBNA1 plasmid. 23 
Cells treated with DMSO control demonstrated high level of PLA signals (1.83 ± 0.54 per cell) further 24 
confirming that the EBNA1 mRNA–NCL interaction takes place in, or at the close vicinity of the nucleus 25 
a) b)
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(Fig. 8a), whereas non-transfected cells did not display PLA signals (Supplementary Fig. S5).  Treatment 1 
with compounds PyDH2 or PhenDH2 both at a concentration of 5 µM significantly reduced both the 2 
number (0.27 ± 0.11 and 0.40 ± 0.21 per cell, in cells treated with PyDH2 and PhenDH2, respectively) 3 
and the intensity of PLA signals (Fig. 8b–d), hence confirming the ability of these new derivatives to 4 
disrupt the EBNA1 mRNA–NCL interaction, in fine leading to the GAr-dependent inhibition of EBNA1 5 
expression and presentation of EBNA1-derived antigenic peptides. A similar effect was observed in 6 
Mutu-1 cells (EBV-infected Burkitt lymphoma B cells expressing endogenous EBNA1): treatment with 7 
5 µM PhenDH2 decreased the average number of PLA signals per cell from 1.68 ± 0.44 to 0.59 ± 0.20 8 
(Fig. 9 and Supplementary Fig. S6). 9 
Finally, to confirm that both hit compounds interfere with NCL binding to G4 structures in EBNA1 10 
mRNA, we performed in vitro RNA pull-down assay using biotin-tagged RNA oligonucleotide g4-EBNA1 11 
and recombinant NCL. Experiments performed in the presence of PyDH2 or PhenDH2 (10 µM) 12 
demonstrated that both compounds reduced the amount of RNA-bound NCL almost 10-fold with 13 
respect to DMSO control (Fig. 10a); in identical conditions, PhenDC3 employed at the same 14 
concentration reduced the amount of bound NCL only two-fold [22]. Of note, negligible binding of NCL 15 
was detected with a non-G4-forming RNA oligonucleotide GM (obtained from g4-EBNA1 by 16 
replacement of guanines critical for G4 formation with A or U residues), demonstrating that RNA 17 
binding of NCL is G4-specific (Fig. 10b). Collectively, these results strongly suggest that PyDH2 and 18 
PhenDH2, similarly but more efficiently than PhenDC3, act by preventing NCL to interact with G4s that 19 
form in the GAr-encoding sequence of EBNA1 mRNA. 20 
19 
 
 1 
Fig. 8. Proximity ligation assay (PLA) performed in H1299 cells transiently expressing EBNA1. a–c) Microscopy 2 
images of cells treated with a) DMSO (compound vehicle, negative control), b) PyDH2 (5 µM), and c) PhenDH2 3 
(5 µM). Nuclei were revealed by DAPI staining and appear in blue; white dots (PLA signals) indicate interaction 4 
between NCL and G4 of EBNA1 mRNA. As previously observed, this interaction mostly takes place in, or at the 5 
close vicinity of the nucleus [22,42]. d) Number of nuclear PLA signals (dots) per cell in H1299 cells expressing 6 
EBNA1 and treated with DMSO (control), PyDH2 (5 µM) or with PhenDH2 (5 µM). Data from two biological 7 
replicates, 100 cells per sample were analyzed. ***, p < 0.001. 8 
 9 
Fig. 9. Proximity ligation assay (PLA) performed in Mutu-1 cells natively expressing EBNA1. a–b) Microscopy 10 
images of cells treated with a) DMSO (compound vehicle, negative control) and b) PhenDH2 (5 µM). Nuclei were 11 
revealed by DAPI staining and appear in blue; white dots (PLA signals) indicate interaction between NCL and G4 12 
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of EBNA1 mRNA. c) Number of nuclear PLA signals (dots) per cell in Mutu-1 cells treated with DMSO (control) or 1 
with PhenDH2 (5 µM). Data from two biological replicates, ≥ 200 cells per sample were analyzed. ***, p < 0.001. 2 
 3 
Fig. 10. RNA pulldown assay to identify the capacity of ligands to prevent NCL binding to G4-RNA. Recombinant 4 
NCL was applied to streptavidin-coupled agarose beads and biotin-tagged RNA oligonucleotides: a) g4-EBNA1; b) 5 
GM (non-G4-forming 18-mer sequence) in the presence of PyDH2 or PhenDH2 (at a concentration of 10 µM) or 6 
DMSO (vehicle) as indicated. The NCL protein still bound to the beads after washing with 800 mM KCl was eluted 7 
(SDS buffer) and analyzed by SDS-PAGE and western blot. 8 
3. DISCUSSION 9 
3.1. In vitro binding to g4-EBNA1: structure–properties relationships 10 
A systematic comparison of 20 derivatives belonging to the same bis(acylhydrazone) family allowed us 11 
to reveal several interesting relationships between the structure of ligands and their affinity to g4-12 
EBNA1. Firstly, the core heterocycle (Ar1) proved to play a crucial role, as all PymDH derivatives 13 
exhibited poor ability to bind and stabilize g4-EBNA1, as demonstrated by the results of both 14 
biophysical techniques (FID assay and fluorescence melting). As evidenced by X-ray structural analysis 15 
(Fig. 2), this is due to the extended linear shape of PymDH derivatives, which ostensibly hampers their 16 
efficient stacking with G-quartets. Considering the whole set of ligands, the following trend can be 17 
deduced with respect to the impact of Ar1 on G4-binding properties: PhenDH > NaphDH ≈ PyDH >> 18 
PymDH. A similar trend, albeit not comprising pyrimidine derivatives, was also observed in other series 19 
of related cationic dicarboxamide derivatives [43,44]. Secondly, within each sub-family of ligands, 20 
derivatives with lateral pyridinium residues (i.e., PyDH1, PymDH1, NaphDH1, and PhenDH1) 21 
systematically demonstrated less efficient binding to G4 structures, in contrast to the derivatives 22 
bearing lateral quinolinium heterocycles. Consistently with literature data on related derivatives [43], 23 
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this fact can be attributed to the limited π-stacking surface of pyridinium derivatives. With respect to 1 
the substitution pattern of lateral quinolinium rings, 4-substituted derivatives (PyDH3 etc.) appeared 2 
more efficient g4-EBNA1 binders than analogous, 6-substituted derivatives (PyDH5 etc.) according to 3 
the FID assay, but this trend was not supported by the results of the fluorescence-melting assay. 4 
Finally, side-chain substituents (R) seem to have little influence on G4-binding properties, even though 5 
their impact could not be comprehensively evaluated due to the limited size of our combinatorial 6 
matrix. On the other hand, the nature of these substituents plays a crucial role for bioavailability of 7 
bis(acylhydrazones), with benzyl substituents are detrimental to drug-like properties due to imparted 8 
high molecular weight and insaturation. Of note, the same structure–properties relationships were 9 
observed with respect to ligand-induced stabilization of two G4-DNA substrates, myc22 (parallel G4-10 
DNA) and 25TAG (hybrid G4-DNA), demonstrating the polyvalence of G4-binding properties of the 11 
novel ligands. Thus, the N-acylhydrazone group appears to be essentially as efficient as the 12 
carboxamide group in the design of cationic poly-heteroaromatic G4 ligands, as can be evidenced from 13 
comparison of the results obtained with PhenDC3 and its acylhydrazone analogue PhenDH2 (the 14 
former appears as a slightly more efficient binder in fluorescence melting assay, but not in the FID 15 
assay). Taken together, these data demonstrate that cationic bis(acylhydrazones) represent a 16 
promising scaffold for G4-DNA and G4-RNA binders, providing wide possibilities for further 17 
functionalization and modulation of physico-chemical properties. 18 
3.2. Effect of compounds on the GAr-dependent synthesis of EBNA1 and immune evasion of EBV 19 
Among the 20 tested bis(acylhydrazones, PyDH2 and PhenDH2 were found to increase EBNA1 20 
expression in a GAr-dependent manner in H1299 cells (Table 2). Remarkably, both compounds 21 
demonstrated high affinity to g4-EBNA1 according to two biophysical methods (fluorescence melting 22 
and FID assay, Fig. 4). These results speak in favor of the expected mechanism for their biological 23 
activity, namely, interference with the NCL-based inhibition of mRNA translation by preventing the 24 
interaction between NCL and G4 structures in EBNA1 mRNA, as further confirmed by PLA and RNA pull-25 
down assays. Considering the absence of selective targeting of G4-RNA with respect to G4-DNA in vitro, 26 
the cellular activity of the two compounds can be attributed to the fact that GAr repeat of EBNA1 27 
mRNA contains a cluster of multiple (≈13) G4-forming sequences, which may be particularly 28 
susceptible to ligand-induced effects such as NCL displacement. Moreover, G4-DNA structures form 29 
only transiently during DNA transactions such as replication, transcription and recombination, and are 30 
otherwise disfavored in the double-stranded DNA context; this is not the case with RNA whose single-31 
stranded nature favors the formation of long-lived secondary motifs such as G4. PLA experiments 32 
provided further support this mechanism, demonstrating the ability of compounds to disrupt the 33 
interaction between NCL and the GAr-encoding sequence of EBNA1 mRNA in cells. Consistently, both 34 
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compounds were found to increase expression of 235GAr-OVA and the level of antigen presentation 1 
in the GAr-OVA model, while having no effect on cells expressing OVA. Considering their low intrinsic 2 
toxicity with respect to Mutu-1 cells (PyDH2: GI50 > 100 µM, PhenDH2: 50 > GI50 > 100 µM), both 3 
compounds may be employed in order to overcome the immune evasion of EBV through reversion of 4 
NCL and GAr-based repression of EBNA1 expression. 5 
Interestingly, four naphthyridine derivatives (NaphDH2–5) demonstrated significant stabilization of 6 
g4-EBNA1, according to fluorescence melting experiments (Fig. 4a), but had not influence on EBNA1 7 
expression (Table 2). This behavior is not without precedent, as it was also observed with pyridostatin 8 
(PDS), another well-studied G4 binder [22], and indicates that ligand-induced stabilization of a G4 9 
structure is not a prerequisite to prevent its interaction with NCL by a competitive mechanism. In fact, 10 
one can imagine that stabilization of G4 structure could even favor their interaction with NCL (cf. Fig. 11 
S3, Supporting Information). Hence, G4 stabilization and ability to interfere with NCL–G4 interaction 12 
may be two independent events. In line, all NaphDH derivatives were significantly less active in 13 
displacing the fluorescence probe TO from g4-EBNA1 (DC50 > 0.5 µM), in contrast to the two biologically 14 
active derivatives, PyDH2 and PhenDH2 (Fig. 4b). This also indicates that FID assay is potentially better 15 
suited for identification of G4-targeting drugs acting through interference with protein binding to G4 16 
structures. Therefore, the different compounds described here, in addition to constitute promising 17 
scaffolds for drugs able to unveil EBV-related tumors to the immune system and more generally to 18 
interfere with G4-RNA binders, may also represent useful tools to decipher the mode of interaction 19 
between cellular factors and G4. 20 
The final aspect of his works is related to the potential applications of G4 ligands in the context of EBV-21 
related cancers. Indeed, since most of EBV-infected individuals does not develop EBV-linked cancers, 22 
it is important to consider the putative effect of drugs on the virus latency, irrespectively of the obvious 23 
application for treating cancers associated to EBV infection. However, in healthy individuals, the latent 24 
infection by EBV is primarily restricted to a specific small pool of memory B cells. Hence, overcoming 25 
the GAr-based inhibition of EBNA1 translation, in addition to unveil EBV-carrying tumor cells to 26 
cytotoxic T cells, should also unveil just a few non-tumoral cells, therefore having no effect on the vast 27 
majority of healthy host cells. The second point is that, because our compounds should unveil all EBV-28 
infected cells to the immune system (given that EBNA1 is expressed in all EBV-infected cells as it is 29 
essential for viral genome replication and maintenance), they would most certainly have applications 30 
as anti-viral agents, thereby probably presenting interesting medical application in fields other than 31 
EBV-related cancers. For example, they may find applications in grafted patients that all receive 32 
immunosuppressive treatments after the graft, which may lead to reactivation of EBV thereby leading 33 
23 
 
to lympho-proliferation. In these patients, elimination of EBV-infected cells prior to the graft may thus 1 
present a clear therapeutic interest. 2 
4. CONCLUSION 3 
In this work, we designed and synthesized a novel series of cationic derivatives representing 4 
bis(acylhydrazone) analogues of the well-studied G-quadruplex ligands PDC (360A) and PhenDC3. We 5 
demonstrated that harnessing the bis(acylhydrazone) motif allows facile generation of series of 6 
derivatives differing in terms of their physico-chemical properties, drug-like character, G4-binding 7 
properties, and biological activity. Specifically, our results demonstrate that the acylhydrazone group 8 
does not significantly impart the G4-binding properties of compounds, as compared with carboxamide 9 
analogues: instead, the binding to G4 structures seems mostly governed by the nature of central and 10 
lateral heterocyclic residues, revealing interesting SARs that can be interpreted in terms of molecular 11 
structure and preorganization of ligands. Even though the modifications of the scaffold explored in this 12 
work were not sufficient to achieve preferential targeting of viral G4-RNA with respect to G4-DNA in 13 
vitro, the results of biological assays demonstrate that two compounds, namely PyDH2 and PhenDH2, 14 
displayed promising biological activity in EBV-related cellular models, being able to interfere with the 15 
GAr-dependent limitation of protein expression and antigen presentation. Moreover, both compounds 16 
were significantly less toxic than the prototype drug PhenDC3 when used at concentrations required 17 
for boosting the production of EBNA1-derived antigenic peptides (i.e., 5–10 µM). Therefore, these 18 
compounds represent promising drug candidates for interfering with the immune evasion of EBV. Last 19 
but not least, the modular bis(acylhydrazone) scaffold presented here represents a promising platform 20 
for the development of novel ligands targeting other therapeutically important G4-RNA and/or G4-21 
DNA structures. 22 
5. EXPERIMENTAL SECTION 23 
5.1. Chemistry 24 
Synthesis and characterization: All commercially available chemicals were reagent grade and used 25 
without further purification. NMR spectra were measured with a Bruker Avance 300 spectrometer (1H: 26 
300 MHz, 13C: 75 MHz) at 25 °C; chemical shifts are given in ppm (δ) values. Multiplicities of 13C NMR 27 
signals were determined from DEPT-135 experiments. The melting points were determined in open-28 
end capillaries with a digital melting point instrument (SMP30, Stuart). Elemental microanalysis of all 29 
novel compounds was performed by the Service de Microanalyse, CNRS–ICSN, Gif-sur-Yvette, France. 30 
The purity of final compounds was assessed by LC/MS analysis (Waters Alliance 2695 equipped with a 31 
Waters XBridge C18-3.5 µm column and a photodiode array detector; eluent A: water with 0.05% TFA, 32 
eluent B: MeCN with 0.05% TFA, gradient elution with 2 to 100% of eluent B). Mass spectra (MS, ESI in 33 
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the positive-ion mode) were recorded with a Waters ZQ instrument (cone voltage: 30 V). In the 1 
assignment of MS of salts, M always refers to the organic dication. 2 
 3 
General procedure for the synthesis of bis(acylhydrazides) (1–4): A solution of the corresponding 4 
dimethyl ester (1.95 g, 10 mmol) and hydrazine hydrate (10.9 mL, 11.2 g, 220 mmol) in ethanol (150 5 
mL) was heated under reflux for 18 h and then cooled to room temperature. The precipitate was 6 
filtered, washed twice with ethanol, once with ether, and dried, to give the bis(acylhydrazide) which 7 
was sufficiently pure and employed without further purification. 8 
Pyridine-2,6-dicarbohydrazide (1) [45]: Yield 1.73 g (89%). White solid, m.p. 285–286 °C (lit. 285 °C); 1H 9 
NMR (300 MHz, DMSO-d6): δ 10.63 (s, 2H), 8.13 (s, 3H), 4.63 (br s, 4H); 13C NMR (75 MHz, DMSO-d6): δ 10 
161.9 (Cq), 148.4 (Cq), 139.3 (CH), 123.7 (CH); MS (ESI+): m/z = 196.2 [M + H]+. 11 
Pyrimidine-4,6-dicarbohydrazide (2): Yield 1.81 g (92%). Pale-yellow solid, m.p. (decomp.) 280 °C; 1H 12 
NMR (300 MHz, DMSO-d6): δ 10.41 (s, 2H), 9.35 (d, J = 1.1 Hz, 1H), 8.35 (d, J = 1.1 Hz, 1H), 4.77 (br s, 13 
4H); 13C NMR (75 MHz, DMSO-d6): δ 160.1 (Cq), 158.4 (Cq), 157.2 (CH), 114.7 (CH); MS (ESI+): m/z = 14 
197.1 [M + H]+. 15 
1,8-Naphthyridine-2,7-dicarbohydrazide (3): Yield 2.45 g (97%). Pale-yellow solid, m.p. > 290 °C; 1H 16 
NMR (300 MHz, DMSO-d6): δ 10.00 (s, 2H), 8.74 (d, J = 8.4 Hz, 2H), 8.25 (d, J = 8.4 Hz, 2H), 4.74 (br s, 17 
4H); 13C NMR (75 MHz, CD3CO2D): δ 164.7 (Cq), 153.1 (Cq), 141.1 (CH), 126.7 (Cq), 122.0 (CH); MS (ESI+): 18 
m/z = 247.1 [M + H]+. 19 
1,10-Phenanthroline-2,9-dicarbohydrazide (4) [46]: Yield 2.38 g (80%). Pale yellow solid, m.p. > 290 °C 20 
(lit. 318–325 °C); 1H NMR (300 MHz, DMSO-d6): δ 10.77 (s, 2H), 8.69 (d, J = 8.3 Hz, 2H), 8.40 (d, J = 8.3 21 
Hz, 2H), 8.14 (s, 2H), 4.78 (br s, 4H); 13C NMR (75 MHz, DMSO-d6): δ 162.9 (Cq), 149.5 (Cq), 144.0 (Cq), 22 
137.9 (CH), 130.1 (Cq), 127.8 (CH), 121.0 (CH); MS (ESI+): m/z = 297.2 [M + H]+. 23 
 24 
Typical procedure for the synthesis of bis(acylhydrazone) precursors (6a–c, 7a–c, 8a–c, and 9a–c): A 25 
solution of a bis(acylhydrazide) (1–4, 2.0 mmol) and a heteroaromatic aldehyde (5a–5c, 4.4 mmol) in 26 
ethanol (10 mL) was heated under reflux for 18 h. After cooling, the precipitate was collected by 27 
filtration, thoroughly washed with ethanol, and dried, to give the corresponding bis(acylhydrazone) 28 
which was sufficiently pure and employed without further purification. 29 
N′2,N′6-Bis(pyridin-4-ylmethylene)pyridine-2,6-dicarbohydrazide (6a): Yield 90%; white powder, m.p. > 30 
290 °C; 1H NMR (300 MHz, DMSO-d6): δ 12.54 (s, 2H), 8.79 (s, 2H), 8.72 (d, J = 5.9 Hz, 4H), 8.44–8.25 31 
25 
 
(m, 3H), 7.77 (d, J = 6.0 Hz, 4H); 13C NMR (75 MHz, DMSO-d6): δ 159.8 (Cq), 150.4 (CH), 148.0 (Cq), 147.6 1 
(CH), 141.3 (Cq), 140.2 (CH), 125.9 (CH), 121.1 (CH); MS (ESI+): m/z = 374.2 [M + H]+, 187.7 [M + 2H]2+. 2 
N′2,N′6-Bis(quinolin-4-ylmethylene)pyridine-2,6-dicarbohydrazide (6b): Yield 93%; pale-yellow solid, 3 
m.p. > 290 °C; 1H NMR (300 MHz, DMSO-d6): δ 12.65 (s, 2H), 9.48 (s, 2H), 9.07 (d, J = 4.5 Hz, 2H), 8.91 4 
(dd, J = 8.4, 0.7 Hz, 2H), 8.53–8.33 (m, 3H), 8.16 (dd, J = 8.3, 0.7 Hz, 2H), 7.99 (d, J = 4.5 Hz, 2H), 7.92–5 
7.79 (m, 4H); 13C NMR (75 MHz, DMSO-d6): δ 159.7 (Cq), 150.5 (CH), 148.5 (Cq), 148.0 (Cq), 147.3 (CH), 6 
140.3 (CH), 137.1 (Cq), 129.9 (CH), 129.8 (CH), 127.7 (CH), 125.9 (CH), 124.8 (Cq), 124.4 (CH), 120.0 (CH); 7 
MS (ESI+): m/z = 474.3 [M + H]+. 8 
N′2,N′6-Bis(quinolin-6-ylmethylene)pyridine-2,6-dicarbohydrazide (6c): Yield 80%; pale-yellow solid, 9 
m.p. > 290 °C; 1H NMR (300 MHz, DMSO-d6): δ 12.50 (s, 2H), 9.01–8.94 (m, 4H), 8.52 (d, J = 7.8 Hz, 2H), 10 
8.46–8.39 (m, 2H), 8.39–8.28 (m, 5H), 8.13 (d, J = 8.8 Hz, 2H), 7.63 (dd, J = 8.3, 4.3 Hz, 2H); 13C NMR (75 11 
MHz, DMSO-d6): δ 159.6 (Cq), 151.5 (CH), 149.2 (CH), 148.6 (Cq), 148.2 (Cq), 140.1 (CH), 136.5 (CH), 12 
132.3 (Cq), 129.8 (CH), 129.0 (CH), 128.0 (Cq), 126.4 (CH), 125.6 (CH), 122.2 (CH); MS (ESI+): m/z = 474.3 13 
[M + H]+, 237.7 [M + 2H]2+. 14 
N′4,N′6-Bis(pyridin-4-ylmethylene)pyrimidine-4,6-dicarbohydrazide (7a): Yield 99%; white solid, m.p. > 15 
290 °C; 1H NMR (300 MHz, DMF-d7): δ 12.77 (s, 2H), 9.60 (s, 1H), 8.89 (s, 2H), 8.80–8.70 (m, 5H), 7.79 16 
(d, J = 6.0 Hz, 4H); 13C NMR (75 MHz, DMF-d7): δ 159.7 (Cq), 159.1 (Cq), 158.0 (CH), 150.9 (CH), 148.8 17 
(CH), 141.9 (Cq), 121.6 (CH), 116.8 (CH); MS (ESI+): m/z = 375.2 [M + H]+, 188.1 [M + 2H]2+. 18 
N′4,N′6-Bis(quinolin-4-ylmethylene)pyrimidine-4,6-dicarbohydrazide (7b): Yield 99%; pale-yellow solid, 19 
m.p. (decomp.) 282 °C; 1H NMR (300 MHz, DMF-d7): δ 12.89 (s, 2H), 9.68 (d, J = 10.9 Hz, 3H), 9.10 (d, J 20 
= 4.4 Hz, 2H), 8.93–8.79 (m, 3H), 8.18 (d, J = 8.2 Hz, 2H), 8.02 (s, 2H), 7.96–7.86 (m, 2H), 7.86–7.76 (m, 21 
2H); 13C NMR (75 MHz, DMF-d7): δ 160.0 (Cq), 157.7 (CH), 150.4 (CH), 149.5 (Cq), 148.4 (CH), 137.9 (Cq), 22 
130.3 (CH), 129.5 (CH), 127.6 (CH), 125.6 (Cq), 124.6 (CH), 123.4 (Cq) 120.3 (CH), 116.8 (CH); MS (ESI+): 23 
m/z = 475.3 [M + H]+, 238.2 [M + 2H]2+.  24 
N′4,N′6-Bis(quinolin-6-ylmethylene)pyrimidine-4,6-dicarbohydrazide (7c): Yield 99%; pale-yellow solid, 25 
m.p. > 290 °C; 1H NMR (300 MHz, DMSO-d6): δ 12.68 (s, 2H), 9.60 (s, 1H), 9.03–8.87 (m, 4H), 8.65 (s, 26 
1H), 8.51 (d, J = 8.0 Hz, 2H), 8.32–8.20 (m, 4H), 8.10 (d, J = 8.4 Hz, 2H), 7.66–7.55 (m, 2H).; 13C NMR (75 27 
MHz, CD3CO2D): δ 160.2 (Cq), 158.6 (Cq), 158.0 (CH), 150.5 (CH), 147.1 (CH), 145.2 (CH), 141.5 (Cq), 28 
134.7 (Cq), 131.0 (CH), 130.6 (CH), 129.0 (Cq), 123.7 (CH), 123.0 (CH), 116.9 (CH); MS (ESI+): m/z = 475.3 29 
[M + H]+, 238.2 [M + 2H]2+. 30 
N′2,N′7-Bis(pyridin-4-ylmethylene)-1,8-naphthyridine-2,7-dicarbohydrazide (8a): Yield 78%; white solid, 31 
m.p. > 290 °C; 1H NMR (300 MHz, DMSO-d6): δ 12.63 (s, 2H), 8.89 (d, J = 8.3 Hz, 2H), 8.81–8.58 (m, 6H), 32 
26 
 
8.42 (d, J = 8.3 Hz, 2H), 7.71 (d, J = 4.6 Hz, 4H); 13C NMR (75 MHz, CD3CO2D): δ 162.7 (Cq), 153.5 (Cq), 1 
149.3 (Cq), 147.1 (CH), 145.3 (CH), 141.5 (CH), 127.7 (Cq), 124.8 (CH), 123.1 (CH); MS (ESI+): m/z = 425.3 2 
[M + H]+. 3 
N′2,N′7-Bis(quinolin-4-ylmethylene)-1,8-naphthyridine-2,7-dicarbohydrazide (8b): Yield 80%; white 4 
solid, m.p. > 290 °C; 1H NMR (300 MHz, DMSO-d6): δ 12.72 (s, 2H), 9.51 (s, 2H), 9.05 (d, J = 4.5 Hz, 2H), 5 
8.93 (d, J = 8.3 Hz, 2H), 8.78 (d, J = 8.3 Hz, 2H), 8.48 (d, J = 8.3 Hz, 2H), 8.14 (d, J = 8.2 Hz, 2H), 7.95 (d, 6 
J = 4.4 Hz, 2H), 7.91–7.84 (m, 2H), 7.84–7.77 (m, 2H); 1H NMR (300 MHz, CD3CO2D/D2O 1:1 v/v): δ 9.36 7 
(s, 2H), 9.02 (d, J = 5.5 Hz, 2H), 8.67–8.55 (m, 4H), 8.36 (dd, J = 13.8, 7.0 Hz, 4H), 8.11 (d, J = 8.4 Hz, 2H), 8 
7.99–7.90 (m, 2H), 7.90–7.80 (m, 2H); 13C NMR (75 MHz, CD3CO2D/D2O 1:1 v/v): δ 162.0 (Cq), 152.7 9 
(Cq), 145.6 (CH), 144.5 (CH), 141.2 (CH), 141.0 (Cq), 134.5 (CH), 130.8 (CH), 127.1 (Cq), 126.4 (Cq), 124.9 10 
(CH), 123.6 (CH), 122.6 (CH), 119.7 (CH); MS (ESI+): m/z = 525.2 [M + H]+, 263.2 [M + 2H]2+. 11 
N′2,N′7-Bis(quinolin-6-ylmethylene)-1,8-naphthyridine-2,7-dicarbohydrazide (8c): Yield 80%; white 12 
solid, m.p. > 290 °C; 1H NMR (300 MHz, DMSO-d6): δ 12.56 (s, 2H), 9.07–8.74 (m, 6H), 8.52 (d, J = 8.3 13 
Hz, 2H), 8.44 (d, J = 8.2 Hz, 2H), 8.33–8.25 (m, 4H), 8.12 (d, J = 8.9 Hz, 2H), 7.62 (dd, J = 7.6, 4.0 Hz, 2H); 14 
13C NMR spectrum could not be obtained due to insufficient solubility; MS (ESI+): m/z = 263.1 [M + 15 
2H]2+. 16 
N′2,N′9-Bis(pyridin-4-ylmethylene)-1,10-phenanthroline-2,9-dicarbohydrazide (9a): Yield 77%; pale 17 
yellow solid, m.p. > 290 °C; 1H NMR (300 MHz, DMF-d7): δ 12.87 (s, 2H), 9.11 (s, 2H), 8.92 (d, J = 8.3 Hz, 18 
2H), 8.81 (d, J = 5.8 Hz, 4H), 8.67 (d, J = 8.3 Hz, 2H), 8.34 (s, 2H), 7.85 (d, J = 5.8 Hz, 4H); NMR (75 MHz, 19 
DMF-d7): δ 161.1 (Cq), 150.9 (CH), 149.8 (Cq), 147.9 (CH), 144.6 (Cq), 142.4 (Cq), 139.0 (CH), 131.5 (Cq), 20 
128.8 (CH), 122.1 (CH), 121.6 (CH); MS (ESI+): m/z = 475.3 [M + H]+. 21 
N′2,N′9-Bis(quinolin-4-ylmethylene)-1,10-phenanthroline-2,9-dicarbohydrazide (9b): Yield 55%; pale 22 
yellow solid, m.p. > 290 °C; 1H NMR (300 MHz, DMSO-d6): δ 12.97 (s, 2H), 9.62 (s, 2H), 8.86–8.83 (m, 23 
4H), 8.65 (d, J = 8.3 Hz, 2H), 8.61 (d, J = 8.2 Hz, 2H), 8.26 (s, 2H), 7.99 (d, J = 8.3 Hz, 2H), 7.81 (d, J = 4.5 24 
Hz, 2H), 7.61–7.53 (m, 2H), 7.10–7.02 (m, 2H); 13C NMR (75 MHz, DMSO-d6): δ 160.4 (Cq), 150.1 (CH), 25 
149.0 (Cq), 148.1 (Cq), 147.3 (CH), 138.8 (CH), 138.1 (CH), 137.8 (Cq), 130.9 (Cq), 129.4 (CH), 129.4 (CH), 26 
128.6 (CH), 126.9 (CH), 124.9 (CH), 124.2 (Cq), 122.0 (CH), 119.6 (CH); MS (ESI+): m/z = 575.3 [M + H]+, 27 
288.2 [M + 2H]2+. 28 
N′2,N′9-Bis(quinolin-6-ylmethylene)-1,10-phenanthroline-2,9-dicarbohydrazide (9c): Yield 59%; pale 29 
yellow solid, m.p. > 290 °C; 1H NMR (300 MHz, DMF-d7): δ 12.88 (s, 2H), 9.37 (s, 2H), 9.01 (dd, J = 4.2, 30 
1.5 Hz, 2H), 8.93 (d, J = 8.3 Hz, 2H), 8.69 (d, J = 8.3 Hz, 2H), 8.48 (dd, J = 8.8, 1.6 Hz, 2H), 8.34 (d, J = 7.4 31 
Hz, 4H), 8.19 (d, J = 8.8 Hz, 2H), 8.11 (d, J = 7.9 Hz, 2H), 7.53 (dd, J = 8.3, 4.2 Hz, 2H); 13C NMR (75 MHz, 32 
DMF-d7): δ 160.8 (Cq), 151.8 (CH), 150.0 (Cq), 149.5 (Cq), 149.5 (CH), 144.5 (Cq), 138.9 (CH), 136.6 (CH), 33 
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133.6 (Cq), 131.4 (Cq), 130.4 (CH), 129.3 (CH), 128.7 (CH), 128.6 (Cq), 127.0 (CH), 122.5 (CH), 122.0 (CH); 1 
MS (ESI+): m/z = 575.3 [M + H]+, 288.2 [M + 2H]2+. 2 
 3 
4-Formyl-1-methylpyridinium iodide (10a):[47] The mixture of pyridine-4-carboxaldehyde (5.4 mL, 4 
6.10 g, 56.9 mmol) and methyl iodide (7.0 mL, 15.95 g, 112.4 mmol) in DCM (20 mL) was stirred for 72 5 
h at room temperature under argon atmosphere. The precipitated solid was filtered and washed twice 6 
with DCM, to give 10a (13.3 g, 94%) as an orange solid. 1H NMR (300 MHz, D2O): δ 8.80 (d, J = 6.5 Hz, 7 
2H), 8.12 (d, J = 6.2 Hz, 2H), 6.21 (s, 1H), 4.39 (s, 3H); 13C NMR (75 MHz, D2O): δ 160.1 (Cq), 146.0 (CH), 8 
125.7 (CH), 88.2 (CH), 48.5 (CH3); MS (ESI+): m/z (%) = 140.1 (100) [M + H2O]+. 9 
 10 
General procedure for the synthesis of quaternized heterocyclic aldehydes (11a–b, 12a–b): The 11 
solution of aldehyde (10 mmol) and alkylating agent (100 mmol) in acetone (18 mL) was stirred at 60 12 
°C for 18 h and then cooled to room temperature. The precipitated solid was filtered, washed twice 13 
with acetone, once with ether, and dried. 14 
4-Formyl-1-methylquinolinium iodide (11a): Obtained from quinoline-4-aldehyde and methyl iodide in 15 
a 77% yield. Red solid, 1H NMR (300 MHz, D2O): δ 9.25 (d, J = 6.1 Hz, 1H), 8.63 (d, J = 8.4 Hz, 1H), 8.42 16 
(d, J = 9.0 Hz, 1H), 8.24 (m, 2H), 8.04 (m, 1H), 6.87 (s, 1H), 4.66 (s, 3H); 13C NMR (75 MHz, D2O): δ 157.8 17 
(Cq), 150.1 (CH), 139.5 (Cq), 135.9 (CH), 130.8 (CH), 127.4 (Cq), 127.1 (CH), 119.5 (CH), 118.5 (CH), 86.8 18 
(CH), 46.3 (CH3); MS (ESI+): m/z (%) = 190.3 (100) [M + H2O]+, 172.1 (25) [M]+. 19 
4-Formyl-1-benzylquinolinium bromide (11b): Obtained from quinoline-4-aldehyde and benzyl 20 
bromide in an 81% yield. 1H NMR (300 MHz, D2O): δ 9.39 (d, J = 6.1 Hz, 1H), 8.63 (d, J = 7.9 Hz, 1H), 21 
8.45–8.25 (m, 2H), 8.15–8.04 (m, 1H), 7.97 (m, 1H), 7.42 (s, 3H), 7.32 (s, 2H), 6.89 (s, 1H), 6.28 (s, 2H); 22 
13C NMR (75 MHz, D2O): δ 158.7 (Cq), 149.9 (CH), 139.0 (Cq), 136.1 (CH), 133.4 (Cq), 130.8 (CH), 130.1 23 
(CH), 129.9 (CH), 128.1 (Cq), 128.0 (CH), 127.4 (CH), 120.0 (CH), 118.7 (CH), 86.9 (CH), 61.8 (CH2); MS 24 
(ESI+): m/z (%) = 266.2 (100) [M + H2O]+, 248.2 (6) [M]+. 25 
6-Formyl-1-ethylquinolinium iodide (12a): Obtained from quinoline-6-aldehyde and ethyl iodide in a 26 
73% yield. 1H NMR (300 MHz, DMSO-d6): δ 10.31 (s, 1H), 9.68 (d, J = 4.7 Hz, 1H), 9.48 (d, J = 8.3 Hz, 1H), 27 
9.08 (d, J = 1.7 Hz, 1H), 8.79 (d, J = 9.2 Hz, 1H), 8.60 (dd, J = 9.2, 1.7 Hz, 1H), 8.31 (dd, J = 8.4, 5.8 Hz, 28 
1H), 5.13 (q, J = 7.2 Hz, 2H), 1.62 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, DMSO-d6): δ 191.9 (Cq), 151.5 29 
(CH), 148.7 (CH), 139.7 (Cq), 135.6 (Cq), 134.4 (CH), 132.5 (CH), 129.6 (Cq), 123.5 (CH), 120.3 (CH), 53.5 30 
(CH2), 15.2 (CH3); MS (ESI+): m/z (%) = 204.2 (8) [M + H2O]+, 186.1 (100) [M]+. 31 
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6-Formyl-1-benzylquinolinium iodide (12b): Obtained from quinoline-6-aldehyde and benzyl bromide 1 
in an 85% yield. 1H NMR (300 MHz, DMSO-d6): δ 10.26 (s, 1H), 9.85 (d, J = 5.8 Hz, 1H), 9.58 (d, J = 8.3 2 
Hz, 1H), 9.10 (d, J = 1.5 Hz, 1H), 8.67 (d, J = 9.2 Hz, 1H), 8.54 (dd, J = 9.2, 1.7 Hz, 1H), 8.41 (dd, J = 8.4, 3 
5.8 Hz, 1H), 7.40 (s, 5H), 6.42 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 191.7 (Cq), 152.5 (CH), 149.6 (CH), 4 
139.9 (Cq), 135.7 (Cq), 134.3 (CH), 133.6 (Cq), 132.8 (CH), 129.9 (CH), 129.1 (Cq), 128.8 (CH), 127.4 (CH), 5 
123.7 (CH), 120.6 (Cq), 60.2 (CH2); MS (ESI+): m/z (%) = 266.3 (10) [M + H2O]+, 248.2 (100) [M]+. 6 
 7 
Synthesis of cationic bis(acylhydrazones) (PyDH1, PyDH2). Method A: A mixture of bis(acylhydrazone) 8 
precursor 6a or 6b (0.5 mmol), alkyl halogenide (75 mmol) and DMF (3 mL) was sealed in a tube and 9 
heated at 40 °C during 18 h. After cooling to room temperature, the precipitate was filtered and 10 
washed with DMF and diethyl ether, and dried in vacuum. The crude product was purified by 11 
recrystallization from boiling MeCN–H2O. Note: this method gave sufficiently pure products PyDH1 and 12 
PyDH2; however, in the case PymDH1, PymDH2, and NaphDH2, the mono-alkylated by-product could 13 
not be removed by recrystallization. Method B (below) was therefore preferred for the synthesis of all 14 
bis(acylhydrazones). 15 
N′2,N′6-Bis[(1-methylpyridinium-4-yl)methylene]pyridine-2,6-dicarbohydrazide iodide (PyDH1): Yield 16 
279 mg (85%). Orange powder; 1H NMR (300 MHz, DMSO-d6): δ 12.93 (s, 2H), 9.03 (d, J = 5.9 Hz, 4H), 17 
8.94 (s, 2H), 8.54–8.31 (m, 7H), 4.37 (s, 6H); 13C NMR (75 MHz, DMSO-d6): δ 160.3 (Cq), 148.8 (Cq), 147.6 18 
(Cq), 146.1 (CH), 143.8 (CH), 140.6 (CH), 126.6 (CH), 124.3 (CH), 47.7 (CH3); MS (ESI+): m/z (%) = 402.3 19 
(100) [M – H]+, 201.7 (41) [M]2+; purity (LC) 100%. 20 
N′2,N′6-Bis[(1-methylquinolinium-4-yl)methylene]pyridine-2,6-dicarbohydrazide iodide (PyDH2): Yield 21 
360 mg (95%). Orange powder; 1H NMR (300 MHz, DMSO-d6): δ 13.03 (s, 2H), 9.74 (s, 2H), 9.54 (d, J = 22 
6.3 Hz, 2H), 9.07 (d, J = 8.5 Hz, 2H), 8.66–8.56 (m, 4H), 8.52 (d, J = 7.0 Hz, 2H), 8.48–8.43 (m, 1H), 8.42–23 
8.33 (m, 2H), 8.27–8.18 (m, 2H), 4.68 (s, 6H); 13C NMR (75 MHz, DMSO-d6): δ 160.1 (Cq), 149.4 (CH), 24 
147.6 (Cq), 147.0 (Cq), 143.4 (CH), 140.7 (CH), 139.1 (Cq), 135.3 (CH), 130.5 (CH), 126.7 (CH), 126.3 (Cq), 25 
126.0 (CH), 120.0 (CH), 119.0 (CH), 45.7 (CH3); MS (ESI+): m/z (%) = 502.3 (100) [M – H]+, 616.3 (9) [M + 26 
CF3COO]+; purity (LC) 90%. 27 
 28 
Synthesis of cationic bis(acylhydrazones). Method B: The mixture of dicarbohydrazide 1–4 (0.5 mmol) 29 
and quaternized aldehyde 10a, 11a–b, or 12a–b (1.1 mmol) in DMF (3 mL) was heated at 100 °C (80 °C 30 
for NaphDH5 and PhenDH5) for 2 h and then cooled to room temperature. The precipitate was 31 
collected by filtration, washed three times with MeCN, once with ether, dried and then additionally 32 
29 
 
recrystallized from MeCN/H2O. The yields are indicated for 1H-NMR spectroscopically pure material 1 
prior to the final recrystallization step. 2 
N′2,N′6-Bis[(1-methylpyridinium-4-yl)methylene]pyridine-2,6-dicarbohydrazide iodide (PyDH1): Yield 3 
90%. The appearance and spectroscopic properties were identical with those described above; purity 4 
(LC): 100%; anal. calcd. for C21H21I2N7O2 × 2 H2O (693.3): C 36.38, H 3.63, N 14.14; found: C 36.03, H 5 
3.31, N 14.05. 6 
N′2,N′6-Bis[(1-methylquinolinium-4-yl)methylene]pyridine-2,6-dicarbohydrazide iodide (PyDH2): Yield 7 
76%. The appearance and spectroscopic properties were identical with those described above; purity 8 
(LC): 100%; anal. calcd. for C29H25I2N7O2 × 3.5 H2O (820.4): C 42.46, H 3.93, N 11.95; found: C 42.46, H 9 
3.59, N 11.60. 10 
N′2,N′6-Bis[(1-benzylquinolinium-4-yl)methylene]pyridine-2,6-dicarbohydrazide bromide (PyDH3): Yield 11 
93%. Yellow-orange powder; 1H NMR (300 MHz, DMSO-d6): δ 13.34 (s, 2H), 10.29 (s, 2H), 9.74 (d, J = 12 
6.2 Hz, 2H), 9.06 (d, J = 8.5 Hz, 2H), 8.66 (d, J = 6.2 Hz, 2H), 8.62–8.50 (m, 4H), 8.49–8.38 (m, 1H), 8.31–13 
8.23 (m, 2H), 8.19–8.11 (m, 2H), 7.41 (s, 10H), 6.42 (s, 4H); 13C NMR (75 MHz, DMSO-d6): δ 160.0 (Cq), 14 
149.4 (CH), 148.3 (Cq), 147.8 (Cq), 143.1 (CH), 140.4 (CH), 138.2 (Cq), 135.5 (CH), 134.0 (Cq), 130.2 (Cq), 15 
129.2 (CH), 128.9 (CH), 127.4 (CH), 127.2 (Cq), 127.0 (CH), 126.3 (CH), 120.0 (CH), 118.4 (CH), 59.9 (CH2); 16 
MS (ESI+): m/z (%) = 654.4 (34) [M – H]+, 327.8 (100) [M]2+; purity (LC): 100%; anal. calcd. for 17 
C41H33Br2N8O2 × 1.5 H2O (842.6): C 58.44, H 4.31, N 11.64; found: C 58.28, H 4.28, N 11.62. 18 
N′2,N′6-Bis[(1-ethylquinolinium-6-yl)methylene]pyridine-2,6-dicarbohydrazide iodide (PyDH4): Yield 19 
92%. Pale brown solid; 1H NMR (300 MHz, DMSO-d6): δ 12.67 (s, 2H), 9.59 (d, J = 5.4 Hz, 2H), 9.38 (d, J 20 
= 8.3 Hz, 2H), 9.07 (s, 2H), 8.85 (s, 2H), 8.74 (q, J = 9.6 Hz, 4H), 8.45 (d, J = 7.1 Hz, 2H), 8.41–8.32 (m, 21 
1H), 8.32–8.16 (m, 2H), 5.14 (q, J = 7.0 Hz, 4H), 1.66 (t, J = 7.0 Hz, 6H); 13C NMR (75 MHz, DMSO-d6): δ 22 
160.0 (Cq), 149.7 (CH), 148.0 (Cq), 147.4 (CH), 147.1 (CH), 140.3 (CH), 138.1 (Cq), 135.2 (CH), 132.3 (CH), 23 
130.1 (Cq), 129.9 (CH), 126.0 (CH), 123.2 (CH), 120.0 (CH), 53.3 (CH2), 15.3 (CH3); MS (ESI+): m/z (%) = 24 
644.3 (32) [M + CF3COO]+, 265.8 (100) [M]2+; purity (LC): 100%; anal. calcd. for C31H29I2N7O2 × 1.5 H2O 25 
(821.5): C 45.33, H 4.05, N 11.94; found: C 45.44, H 4.11, N 11.96. 26 
N′2,N′6-Bis[(1-benzylquinolinium-6-yl)methylene]pyridine-2,6-dicarbohydrazide bromide (PyDH5): Yield 27 
55%. Pale yellow solid; 1H NMR (300 MHz, DMSO-d6): δ 12.72 (s, 2H), 9.76 (d, J = 5.0 Hz, 2H), 9.48 (d, J 28 
= 8.3 Hz, 2H), 9.12 (s, 2H), 8.85 (s, 2H), 8.73–8.58 (m, 4H), 8.46–8.30 (m, 5H), 7.49–7.34 (m, 10H), 6.41 29 
(s, 4H); 13C NMR (75 MHz, DMSO-d6): δ 159.9 (Cq), 150.6 (CH), 148.3 (CH), 148.1 (Cq), 146.9 (CH), 140.2 30 
(CH), 138.3 (Cq), 135.4 (Cq), 133.8 (Cq), 132.6 (CH), 130.4 (Cq), 129.7 (CH), 129.1 (CH), 128.9 (CH), 127.5 31 
(CH), 126.1 (CH), 123.3 (CH), 120.3 (CH), 60.0 (CH2); MS (ESI+): m/z (%) = 768.3 (59) [M + CF3COO]+, 32 
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327.8 (100) [M]2+; purity (LC): 99%; anal. calcd. for C41H33Br2N7O2 × 1.5 H2O (842.6): C 58.44, H 4.31, N 1 
11.64; found: C 58.74, H 4.42, N 11.56. 2 
N′4,N′6-Bis[(1-methylpyridinium-4-yl)methylene]pyrimidine-4,6-dicarbohydrazide iodide (PymDH1): 3 
Yield 97%. Yellow-orange solid; 1H NMR (300 MHz, DMSO-d6): δ 13.31 (s, 2H), 9.67 (s, 1H), 9.01 (d, J = 4 
6.5 Hz, 4H), 8.86 (s, 2H), 8.64 (s, 1H), 8.38 (d, J = 6.4 Hz, 4H), 4.35 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 5 
δ 159.9 (Cq), 158.2 (Cq), 157.7 (CH), 148.6 (Cq), 146.0 (CH), 144.9 (CH), 124.5 (CH), 119.3 (CH), 47.7 6 
(CH3); MS (ESI+): m/z (%) = 403.3 (35) [M – H]+, 202.2 (100) [M]2+; purity (LC): 100%; anal. calcd. for 7 
C20H20I2N8O2 × H2O (676.3): C 35.52, H 3.28, N 16.57; found: C 35.13, H 3.33, N 16.29. 8 
N′4,N′6-Bis[(1-methylquinolinium-4-yl)methylene]pyrimidine-4,6-dicarbohydrazide iodide (PymDH2): 9 
Yield 92%. Orange solid; 1H NMR (300 MHz, DMSO-d6): δ 13.28 (s, 2H), 9.75 (s, 1H), 9.70 (s, 2H), 9.51 10 
(d, J = 6.2 Hz, 2H), 8.86 (d, J = 8.4 Hz, 2H), 8.73 (s, 1H), 8.60 (d, J = 8.7 Hz, 2H), 8.52 (d, J = 6.1 Hz, 2H), 11 
8.40–8.32 (m, 2H), 8.25–8.16 (m, 2H), 4.67 (s, 6H); 13C NMR (75 MHz, DMSO-d6): δ 159.6 (Cq), 158.0 12 
(Cq), 157.8 (CH), 149.4 (CH), 146.7 (Cq), 144.3 (CH), 139.0 (Cq), 135.3 (CH), 130.6 (CH), 126.3 (Cq), 125.6 13 
(CH), 120.0 (CH), 118.8 (CH), 117.0 (CH), 45.7 (CH3); MS (ESI+): m/z (%) = 503.3 (12) [M – H]+, 252.3 (100) 14 
[M]2+; purity (LC): 100%; anal. calcd. for C28H24I2N8O2 × 2.2 H2O (798.0): C 42.18, H 3.58, N 14.05; found: 15 
C 42.55, H 3.39, N 13.66. 16 
N′2,N′6-Bis[(1-benzylquinolinium-4-yl)methylene]pyridine-2,6-dicarbohydrazide bromide (PymDH3): 17 
Yield 93%. Brown crystals. 1H NMR (300 MHz, DMSO-d6): δ 13.31 (s, 2H), 9.74 (d, J = 5.3 Hz, 5H), 8.85 18 
(d, J = 8.7 Hz, 2H), 8.74 (s, 1H), 8.60 (dd, J = 17.3, 7.6 Hz, 4H), 8.33–8.22 (m, 2H), 8.20–8.12 (m, 2H), 19 
7.40 (s, 10H), 6.42 (s, 4H); 13C NMR (75 MHz, DMSO-d6): δ 159.7 (Cq), 158.1 (Cq), 157.8 (CH), 149.6 (CH), 20 
147.9 (Cq), 144.3 (CH), 138.2 (Cq), 135.5 (CH), 134.0 (Cq), 130.5 (CH), 129.1 (CH), 128.8 (CH), 127.2 (CH), 21 
127.2 (Cq), 126.1 (CH), 120.1 (CH), 119.2 (CH), 117.1 (CH), 60.0 (CH2); MS (ESI+): m/z (%) = 655.5 (12) 22 
[M – H]+, 328.4 (100) [M]2+; purity (LC): 100%; anal. calcd. for C40H32Br2N8O2 × H2O (834.6): C 57.57, H 23 
4.11, N 13.43; found: C 57.43, H 4.25, N 13.62. 24 
N′2,N′6-Bis[(1-ethylquinolinium-6-yl)methylene]pyridine-2,6-dicarbohydrazide iodide (PymDH4): Yield 25 
96%. Orange solid. 1H NMR (300 MHz, DMSO-d6): δ 12.93 (s, 2H), 9.65 (s, 1H), 9.57 (d, J = 5.7 Hz, 2H), 26 
9.37 (d, J = 8.3 Hz, 2H), 9.00 (s, 2H), 8.80–8.61 (m, 7H), 8.25 (dd, J = 8.3, 5.9 Hz, 2H), 5.12 (q, J = 7.2 Hz, 27 
4H), 1.64 (t, J = 7.2 Hz, 6H); 13C NMR (75 MHz, DMSO-d6): δ 159.4 (Cq), 158.6 (CH), 149.7 (CH), 148.0 28 
(CH), 147.5 (CH), 138.2 (Cq), 138.1 (Cq), 135.1 (Cq), 132.3 (CH), 130.1 (CH), 130.1 (Cq), 123.2 (CH), 119.9 29 
(CH), 116.8 (CH), 53.2 (CH2), 15.3 (CH3); MS (ESI+): m/z (%) = 266.3 (100) [M]2+; purity (LC): 100%; anal. 30 
calcd. for C30H28I2N8O2 × 3.2 H2O (844.1): C 42.69, H 4.11, N 13.28; found: C 42.34, H 3.84, N 13.25. 31 
N′2,N′6-Bis[(1-benzylquinolinium-6-yl)methylene]pyridine-2,6-dicarbohydrazide bromide (PymDH5): 32 
Yield 97%. Pale-yellow solid. 1H NMR (300 MHz, DMSO-d6): δ 12.91 (s, 2H), 9.74 (d, J = 5.4 Hz, 2H), 9.62 33 
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(d, J = 1.2 Hz, 1H), 9.46 (d, J = 8.3 Hz, 2H), 8.96 (s, 2H), 8.80 (s, 2H), 8.67 – 8.55 (m, 5H), 8.34 (dd, J = 1 
8.3, 5.9 Hz, 2H), 7.47–7.37 (m, 10H), 6.39 (s, 4H); 13C NMR spectrum could not be obtained due to 2 
insufficient solubility; MS (ESI+): m/z (%) = 769.5 (7) [M + CF3COO]+, 328.3 (100) [M]2+; purity (LC): 99%; 3 
anal. calcd. for C40H32Br2N8O2 × 2 H2O (852.6): C 56.35, H 4.26, N 13.14; found: C 56.09, H 4.20, N 13.21. 4 
N′2,N′7-Bis[(1-methylpyridinium-4-yl)methylene]-1,8-naphthyridine-2,7-dicarbohydrazide iodide 5 
(NaphDH1): Yield 76%. Yellow solid; 1H NMR (300 MHz, DMSO-d6): δ 13.14 (s, 2H), 9.01 (d, J = 6.0 Hz, 6 
4H), 8.94 (d, J = 8.3 Hz, 2H), 8.83 (s, 2H), 8.45 (d, J = 8.3 Hz, 2H), 8.39 (d, J = 5.9 Hz, 4H), 4.36 (s, 6H); 13C 7 
NMR (75 MHz, DMSO-d6): δ 161.6 (Cq), 153.5 (Cq), 152.5 (Cq), 148.9 (Cq), 146.0 (CH), 143.7 (CH), 140.4 8 
(CH), 139.1 (Cq), 124.4 (CH), 122.1 (CH), 47.7 (CH3); MS (ESI+): m/z (%) = 453.3 (78) [M – H]+, 227.3 (92) 9 
[M]2+; purity (LC): 100%; anal. calcd. for C24H22I2N8O2 × 0.5 H2O (717.3): C 40.19, H 3.23, N 15.62; found: 10 
C 40.29, H 3.47, N 15.56. 11 
N′2,N′7-Bis[(1-methylquinolinium-4-yl)methylene]-1,8-naphthyridine-2,7-dicarbohydrazide iodide 12 
(NaphDH2): This compound was obtained in an analytically pure form through a reaction of 3 with 11a 13 
performed in DMSO instead of DMF. Yield 81%. Red solid; 1H NMR (300 MHz, DMSO-d6): δ 13.14 (s, 14 
2H), 9.72 (s, 2H), 9.52 (d, J = 6.2 Hz, 2H), 8.99 (d, J = 8.3 Hz, 2H), 8.90 (d, J = 8.4 Hz, 2H), 8.68–8.47 (m, 15 
6H), 8.39–8.32 (m, 2H), 8.25–8.15 (m, 2H), 4.67 (s, 6H); 13C NMR spectrum could not be obtained due 16 
to insufficient solubility; MS (ESI+): m/z (%) = 553.2 (63) [M – H]+, 277.3 (100) [M]2+; purity (LC): 100%; 17 
anal. calcd. for C32H26I2N8O2 × 0.6 DMSO (855.3): C 46.62, H 3.49, N 13.10; found: C 46.77, H 3.23, N 18 
13.45. 19 
N′2,N′7-Bis[(1-benzylquinolinium-4-yl)methylene]-1,8-naphthyridine-2,7-dicarbohydrazide bromide 20 
(NaphDH3): Yield 90%. Yellow solid; 1H NMR (300 MHz, DMSO-d6): δ 13.19 (s, 2H), 9.77 (s, 4H), 9.00 (d, 21 
J = 8.3 Hz, 2H), 8.90 (d, J = 8.1 Hz, 2H), 8.66 (d, J = 6.0 Hz, 2H), 8.56 (dd, J = 16.8, 8.7 Hz, 4H), 8.32–8.22 22 
(m, 2H), 8.21–8.12 (m, 2H), 7.41 (s, 10H), 6.44 (s, 4H); 13C NMR (75 MHz, DMSO-d6): δ 161.3 (Cq), 153.2 23 
(Cq), 152.4 (Cq), 149.6 (CH), 148.2 (Cq), 143.1 (CH), 140.6 (CH), 138.2 (Cq), 135.5 (CH), 134.1 (Cq), 130.5 24 
(CH), 129.1 (CH), 128.8 (CH), 127.3 (CH), 127.1 (Cq), 126.1 (CH), 122.0 (CH), 120.2 (CH), 119.0 (CH), 60.0 25 
(CH2); MS (ESI+): m/z (%) = 705.4 (50) [M – H]+, 353.4 (100) [M]2+; purity (LC): 97%; anal. calcd. for 26 
C44H34Br2N8O2 × 3 H2O (920.7): C 57.40, H 4.38, N 12.17; found: C 57.28, H 4.21, N 12.11. 27 
N′2,N′7-Bis[(1-ethylquinolinium-6-yl)methylene]-1,8-naphthyridine-2,7-dicarbohydrazide iodide 28 
(NaphDH4): Yield 68%. Pale brown solid; 1H NMR (300 MHz, DMSO-d6): δ 12.79 (s, 2H), 9.58 (d, J = 5.9 29 
Hz, 2H), 9.38 (d, J = 8.6 Hz, 2H), 8.99 (s, 2H), 8.93 (d, J = 8.4 Hz, 2H), 8.72 (dd, J = 20.4, 11.1 Hz, 6H), 30 
8.45 (d, J = 8.3 Hz, 2H), 8.26 (dd, J = 8.3, 5.8 Hz, 2H), 5.13 (q, J = 7.2 Hz, 4H), 1.65 (t, J = 7.1 Hz, 6H); 13C 31 
NMR (75 MHz, DMSO-d6): δ 161.1 (Cq), 153.8 (Cq), 152.5 (Cq), 149.6 (CH), 148.5 (Cq), 147.4 (CH), 146.8 32 
(CH), 140.3 (CH), 138.0 (Cq), 135.3 (Cq), 132.4 (CH), 130.1 (Cq), 129.9 (CH), 123.2 (CH), 121.8 (CH), 119.9 33 
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(CH), 53.3 (CH2), 15.3 (CH3); MS (ESI+): m/z (%) = 695.4 (15) [M + CF3COO]+, 291.3 (100) [M]2+; purity 1 
(LC): 100%; anal. calcd. for C34H30I2N8O2 × 1.5 H2O (863.5): C 47.29, H 3.85, N 12.98; found: C 47.44, H 2 
4.11, N 12.95. 3 
N′2,N′7-Bis[(1-benzylquinolinium-6-yl)methylene]-1,8-naphthyridine-2,7-dicarbohydrazide bromide 4 
(NaphDH5): Yield 80%. Pale brown solid; 1H NMR (300 MHz, DMSO-d6): δ 12.76 (s, 2H), 9.75 (d, J = 5.6 5 
Hz, 2H), 9.48 (d, J = 8.3 Hz, 2H), 8.98–8.85 (m, 4H), 8.80 (s, 2H), 8.63 (m, 4H), 8.43 (d, J = 8.3 Hz, 2H), 6 
8.35 (dd, J = 8.2, 5.9 Hz, 2H), 7.41 (d, J = 6.6 Hz, 10H), 6.40 (s, 4H); 13C NMR (75 MHz, DMSO-d6): δ 161.1 7 
(Cq), 153.8 (Cq), 152.6 (Cq), 150.6 (CH), 148.3 (CH), 146.7 (CH), 140.3 (CH), 138.3 (Cq), 135.5 (Cq), 133.8 8 
(Cq), 132.7 (CH), 130.6 (Cq), 129.8 (CH), 129.2 (Cq), 128.9 (CH), 127.5 (CH), 123.3 (CH), 121.8 (CH), 120.3 9 
(CH), 60.1 (CH2); MS (ESI+): m/z (%) = 705.4 (5) [M + CF3COO]+, 353.2 (100) [M]2+; purity (LC): 100%; 10 
anal. calcd. for C44H34Br2N8O2 × H2O (884.6): C 59.74, H 4.10, N 12.67; found: C 59.55, H 4.44, N 12.56. 11 
N′2,N′9-Bis[(1-methylpyridinium-4-yl)methylene]-1,10-phenanthroline-2,9-dicarbohydrazide iodide 12 
(PhenDH1): Yield 50%. Yellow solid; 1H NMR (300 MHz, DMSO-d6): δ 13.38 (s, 2H), 9.04 (s, 6H), 8.89 (d, 13 
J = 8.1 Hz, 2H), 8.64 (d, J = 8.0 Hz, 2H), 8.41 (d, J = 5.9 Hz, 4H), 8.32 (s, 2H), 4.41 (s, 6H), 13C NMR (75 14 
MHz, DMSO-d6): δ 161.1 (Cq), 149.3 (Cq), 148.6 (Cq), 146.0 (CH), 144.3 (CH), 143.7 (Cq), 138.9 (CH), 131.1 15 
(Cq), 128.8 (CH), 124.4 (CH), 122.2 (CH), 47.7 (CH3); MS (ESI+): m/z (%) = 617.3 (20) [M + CF3COO]+, 503.3 16 
(90) [M – H]+, 252.2 (100%) [M]2+; purity (LC): 100%; anal. calcd. for C28H24I2N8O2 × 4.6 H2O (841.2): C 17 
39.98, H 3.98, N 13.32; found: C 40.36, H 4.20, N 12.95. 18 
N′2,N′9-Bis[(1-methylquinolinium-4-yl)methylene]-1,10-phenanthroline-2,9-dicarbohydrazide iodide 19 
(PhenDH2): Yield 78%. Dark-red solid; 1H NMR (300 MHz, DMSO-d6): δ 13.28 (s, 2H), 9.86 (s, 2H), 9.45 20 
(d, J = 6.3 Hz, 2H), 8.95 (d, J = 8.3 Hz, 2H), 8.71 (d, J = 8.3 Hz, 2H), 8.56 (d, J = 6.1 Hz, 2H), 8.48–8.34 (m, 21 
4H), 8.27 (d, J = 9.1 Hz, 2H), 7.88–7.80 (m, 2H), 7.15–7.08 (m, 2H), 4.62 (s, 6H); 13C NMR (75 MHz, 22 
DMSO-d6): δ 160.6 (Cq), 149.3 (Cq), 148.3 (Cq), 147.3 (Cq), 143.6 (Cq), 143.5 (CH), 139.1 (CH), 138.2 (Cq), 23 
134.6 (CH), 131.2 (Cq), 129.2 (CH), 128.8 (CH), 126.1 (Cq), 125.1 (CH), 122.1 (CH), 119.2 (CH), 118.0 (CH), 24 
45.5 (CH3); MS (ESI+): m/z (%) = 717.4 (14) [M + CF3COO]+, 603.4 (83) [M – H]+, 302.3 (100) [M]2+; purity 25 
(LC): 100%; anal. calcd. for C36H28I2N8O2 × 5.7 H2O (961.2): C 44.99, H 4.13, N 11.66; found: C 45.23, H 26 
4.52, N 11.63. 27 
N′2,N′9-Bis[(1-benzylquinolinium-4-yl)methylene]-1,10-phenanthroline-2,9-dicarbohydrazide bromide 28 
(PhenDH3): Yield 87%. Pale brown solid; 1H NMR (300 MHz, DMSO-d6): δ 13.34 (s, 2H), 9.94 (s, 2H), 29 
9.76 (d, J = 6.0 Hz, 2H), 8.96 (d, J = 8.2 Hz, 2H), 8.73 (d, J = 7.7 Hz, 4H), 8.37 (d, J = 7.9 Hz, 4H), 8.14 (d, 30 
J = 9.2 Hz, 2H), 7.65–7.30 (m, 10H), 7.09–7.00 (m, 2H), 6.84–6.79 (m, 2H), 6.35 (s, 4H); 13C NMR (75 31 
MHz, DMSO-d6): δ 160.7 (Cq), 149.6 (CH), 148.4 (Cq), 148.2 (Cq), 143.7 (Cq), 143.2 (CH), 139.1 (CH), 137.5 32 
(Cq), 134.3 (CH), 134.2 (Cq), 131.2 (Cq), 129.2 (CH), 128.9 (CH), 128.8 (CH), 127.3 (Cq), 126.9 (Cq), 125.7 33 
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(CH), 122.2 (CH), 119.4 (CH), 118.3 (CH), 118.3 (CH), 59.8 (CH2); MS (ESI+): m/z (%) = 755.4 (20) [M – 1 
H]+, 378.4 (100) [M]2+; purity (LC): 100%; anal. calcd. for C48H36Br2N8O2 × 3.5 H2O (979.7): C 58.85, H 2 
4.42, N 11.44; found: C 58.84, H 4.30, N 11.47. 3 
N′2,N′9-Bis[(1-ethylquinolinium-6-yl)methylene]-1,10-phenanthroline-2,9-dicarbohydrazide iodide 4 
(PhenDH4): Yield 72%. Pale brown solid; 1H NMR (300 MHz, DMSO-d6): δ 13.10 (s, 2H), 9.60 (d, J = 5.6 5 
Hz, 2H), 9.25 (s, 2H), 9.17 (d, J = 8.2 Hz, 2H), 8.89 (d, J = 8.3 Hz, 2H), 8.76 (d, J = 2.6 Hz, 6H), 8.64 (d, J = 6 
8.3 Hz, 2H), 8.32 (s, 2H), 8.22 (dd, J = 8.4, 5.9 Hz, 2H), 5.16 (q, J = 7.0 Hz, 4H), 1.67 (t, J = 7.1 Hz, 6H); 13C 7 
NMR (75 MHz, DMSO-d6): δ 160.7 (Cq), 149.6 (CH), 149.0 (Cq), 147.3 (Cq), 147.2 (CH), 143.7 (Cq), 8 
138.7(CH), 138.0 (Cq), 135.7 (Cq), 132.8 (CH), 130.9 (Cq), 130.1 (Cq), 129.3 (CH), 128.5 (CH), 123.2 (CH), 9 
122.0 (CH), 120.0 (CH), 53.3 (CH2), 15.4 (CH3); MS (ESI+): m/z (%) = 745.4 (28) [M + CF3COO]+, 316.2 10 
(100) [M]2+; purity (LC): 98%; anal. calcd. for C38H32I2N8O2 × 1.5 H2O (904.5): C 50.46, H 3.79, N 12.39; 11 
found: C 50.13, H 3.90, N 12.41. 12 
N′2,N′9-Bis[(1-benzylquinolinium-6-yl)methylene]-1,10-phenanthroline-2,9-dicarbohydrazide bromide 13 
(PhenDH5): Yield 91%. Pale brown solid; 1H NMR (300 MHz, DMSO-d6): δ 13.10 (s, 2H), 9.79 (d, J = 5.7 14 
Hz, 2H), 9.30 (d, J = 8.3 Hz, 2H), 9.21 (s, 2H), 8.87 (d, J = 8.3 Hz, 2H), 8.81 (s, 2H), 8.76–8.65 (m, 4H), 15 
8.63 (d, J = 8.3 Hz, 2H), 8.39–8.28 (m, 4H), 7.53–7.37 (m, 10H), 6.46 (s, 4H); 13C NMR (75 MHz, DMSO-16 
d6): δ 160.7 (Cq), 150.5 (CH), 149.0 (Cq), 148.1 (CH), 147.0 (CH), 143.8 (Cq), 138.7 (CH), 138.3 (Cq), 135.9 17 
(Cq), 133.8 (Cq), 133.0 (CH), 130.9 (Cq), 130.4 (Cq), 129.5 (CH), 129.2 (CH), 128.9 (CH), 128.6 (CH), 127.6 18 
(CH), 123.4 (CH), 122.0 (CH), 120.3 (CH), 60.1 (CH2); MS (ESI+): m/z (%) = 755.4 (5) [M – H]+, 378.4 (100) 19 
[M]2+; purity (LC): 100%; anal. calcd. for C48H36Br2N8O2 × 2 H2O (952.7): C 60.51, H 4.23, N 11.76; found: 20 
C 60.76, H 4.39, N 11.77. 21 
5.2. Single-crystal X-ray diffraction analysis 22 
X-ray diffraction data for PyDH1 (2I–) were collected using a VENTURE PHOTON100 CMOS Bruker 23 
diffractometer with Micro-focus IuS source Mo Kα radiation. X-ray diffraction data for PymDH1 (2I–) 24 
were collected using a X8 APEXII CCD Bruker diffractometer with graphite-monochromated Mo Kα 25 
radiation. X-ray diffraction data for PhenDH1 (2I–) were collected using a VENTURE PHOTON100 CMOS 26 
Bruker diffractometer with Micro-focus IuS source Cu Kα radiation. All crystals were mounted on a 27 
CryoLoop (Hampton Research) with Paratone-N (Hampton Research) as cryoprotectant and then flash-28 
frozen in a nitrogen gas stream at 100 K.  For compounds, the temperature of the crystal was 29 
maintained at the selected value by means of a 700 series Cryostream (for X8) or N-Helix (for VENTURE) 30 
cooling device within an accuracy of ±1 K. The data were corrected for Lorentz polarization, and 31 
absorption effects. The structures were solved by direct methods using SHELXS-97 [48] and refined 32 
against F2 by full-matrix least-squares techniques using SHELXL-2018 [49] with anisotropic 33 
34 
 
displacement parameters for all non-hydrogen atoms. All calculations were performed using the 1 
Crystal Structure crystallographic software package WINGX [50]. The crystal data collection and 2 
refinement parameters are given in Table S3. CCDC 1881844–1881846 contain the supplementary 3 
crystallographic data for this paper. These data can be obtained free of charge from the Cambridge 4 
Crystallographic Data Centre via https://www.ccdc.cam.ac.uk/structures/. 5 
5.3. Biophysical assays 6 
5.3.1. Fluorescence melting assay 7 
The assay was performed with a double-labeled oligoribonucleotide (g4-EBNA1, 5′-FAM-8 
r(GGGGCAGGAGCAGGAGGA)-TAMRA-3′), which was annealed prior to experiments (95 °C, 5 min) in K-9 
10 buffer (10 mM LiAsO2Me2, 10 mM KCl, 90 mM LiCl, pH 7.3) at a concentration of 10 µM. Double-10 
stranded DNA competitor (ds26, 5′-CAATCGGATCGAATTCGATCCGATTG-3′) was annealed in the same 11 
buffer at a strand concentration of 200 µM. Thermal denaturation runs were performed in 96-well 12 
plates with a real-time PCR apparatus (7900HT Fast Real-Time PCR, Applied Biosystems) using a heating 13 
ramp of 0.5 °C per minute from 25 to 95 °C; the fluorescence intensity was monitored in the FAM 14 
channel. Each well contained 0.2 µM of double-labeled g4-EBNA1, 1 µM of tested compound, and/or 15 
0, 3 or 10 µM of ds26 competitor, in a total volume of 25 µL of K10 buffer. The denaturation 16 
temperatures (Tm) were determined from the maxima of first-derivative plots of FAM emission 17 
intensity vs. temperature, and ligand-induced Tm shifts (ΔTm) were calculated as a difference of mean 18 
denaturation temperatures in the presence and in the absence of ligands (Tm0 = 58.6 °C), from three 19 
independent experiments. Analogous experiments were performed with G4-forming DNA 20 
oligonucleotides F-myc22-T: 5′-FAM-d(TGAGGGTGGGTAGGGTGGGTAA)-TAMRA-3′ and F-25TAG-T: 5′-21 
FAM-d(TAGGGTTAGGGTTAGGGTTAGGGAA)-TAMRA-3′, in K-1 (10 mM LiAsO2Me2, 1 mM KCl, 99 mM 22 
LiCl, pH 7.3) and K-100 (10 mM LiAsO2Me2, 100 mM KCl, pH 7.3) buffers, respectively. 23 
5.3.2. TO displacement assay 24 
This assay is performed in a 96-well microplate format as described [39]. The non-labeled g4-EBNA1 25 
oligoribonucleotide was annealed (95 °C, 5 min) in K100 buffer (10 mM KAsO2Me2, 100 mM KCl, 1 mM 26 
EDTA, 1% v/v DMSO) at a concentration of 5 µM and, after cooling, supplemented with TO (10 µM). 27 
Every row of a black-bottom, 96-well microplate was filled with K100 buffer (q.s.p. 200 μL per well), 28 
pre-folded g4-EBNA1 + TO solution (final concentrations: 0.25 and 0.5 µM, respectively), and an 29 
extemporaneously prepared ligand solution (5 µM in the same buffer; final ligand concentration: 0 to 30 
2.5 μM). After 5 min of orbital shaking, fluorescence intensity was measured with a Fluostar Omega 31 
microplate reader (BMG Labtech) using the following parameters: 20 flashes per well, emission / 32 
excitation filters: 485 / 520 nm, gain adjusted at 80% of the fluorescence from the most fluorescent 33 
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well. The experiments were performed in duplicate. The percentage of TO displacement was calculated 1 
from the fluorescence intensity (F) as %(TO displacement) = 100 × (1 – F / F0), where F0 is the 2 
fluorescence intensity of TO–RNA complex in the absence of ligands. The percentage of displacement 3 
was plotted against the concentration of added ligand, and ligand affinity was characterized by the 4 
concentration required to decrease the fluorescence of the probe by 50% (DC50) after interpolation of 5 
the displacement curve. A control experiment was performed at identical conditions with double-6 
stranded DNA substrate ds26. 7 
5.4. Biological assays 8 
5.4.1. EBNA1 expression assay 9 
The human lung carcinoma cell line H1299 was cultured in RPMI-1640 medium supplemented with 10 
10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U mL−1 penicillin, and 100 µg mL−1 streptomycin. 11 
All cells were cultured at 37 °C with 5% CO2. Transient transfections were performed using Genejuice 12 
reagent (Merck Bioscience) according to the manufacturer’s protocol. For cell treatments with the 13 
indicated G4 ligands or PhenDC3, cells were incubated with 10 µM of drug for 40 h after transfection. 14 
Stock solutions of drugs were prepared in DMSO (Euromedex). Whole-cell lysates were prepared 48 h 15 
post-transfection, and protein concentration was determined using a Bradford assay. Samples were 16 
electrophoretically separated in NuPAGE® Bis-Tris gels 10% (Invitrogen), transferred onto 0.45 µm 17 
nitrocellulose membranes (GE) and blotted under standard conditions using the following antibodies: 18 
anti-GAPDH (Sigma, 1:5,000), anti-EBNA1 mouse monoclonal antibody (OT1X, 1:2,000) or anti-OVA 19 
rabbit polyclonal antibody (C6534 Sigma, 1:2,500). The membranes were then washed with fresh PBS, 20 
1X 0.1% Igepal and incubated for 45 min with swine anti-rabbit or goat anti-mouse secondary 21 
antibodies (Dako) conjugated to horseradish peroxidase at a 1:3,000 dilution, and analyzed by 22 
enhanced chemiluminescence (ECL, GE Healthcare) using a Chemistart 5000 imager (Vilber–Lourmat). 23 
All experiments were repeated at least three times. Relative protein levels for each sample were 24 
normalized to GAPDH or Actin levels as indicated, using Fusion-Capt Advance software. 25 
5.4.2. Antigen presentation assay 26 
Naive OVA257–264 specific CD8+ T cells were isolated by negative selection from peripheral and 27 
mesenteric lymph nodes of a 12-week-old female OT-I mice using the CD8+ T cell isolation kit (Miltenyi 28 
Biotec, Germany). Afterwards, CD8+ T cells were co-cultured with H1299 cells co-transfected with 29 
mouse Kb expression vector and the indicated constructs. For all assays, 105 H1299 cells were 30 
harvested 40 h after treatment and co-incubated with 4 × 105 CD8+ T cells at 37 °C in humidified air/CO2 31 
atmosphere in RPMI medium containing 10% FBS, 4 mM L-glutamine, 100 U mL−1 penicillin, 100 µg 32 
mL−1 streptomycin, 5 mM HEPES and 0.05 mM 2-mercaptoethanol. After 3 days of co-incubation, 33 
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supernatants were collected and IL-2 levels were measured employing the IL-2 ELISA MAX™ Standard 1 
kit (Biolegend, USA) according to the manufacturer’s instructions. 2 
5.4.3. MTT toxicity assay 3 
About 30,000 Mutu-1 cells (derived from an EBV-positive Burkitt’s lymphoma biopsy specimen from a 4 
Kenyan patient) were plated in 0.1 mL per well in 96-well, flat-bottom plates and exposed to the 5 
indicated compounds at the indicated concentrations or DMSO (vehicle). After indicated time (24 or 6 
48 h), 10 µL of MTT solution (5 mg mL−1, CT01-5, Merck Millipore) in PBS (pH 7.4) was added to each 7 
well and incubated for 4 h. A mixture of isopropanol / 0.1 N HCl / 10% Triton X-100 (0.1 mL) was added 8 
to each well to dissolve the formazan crystals, and the absorbance was then measured at 540 nm. 9 
5.4.4. PLA assay 10 
H1299 cells were transfected with an EBNA1 construct and, 7 h post-transfection, treated with the 11 
tested compounds during 40 h. In the experiments with Mutu-1 cells expressing endogenous EBNA1 12 
mRNA, drug treatment was carried out during 36 h. Following compounds administration, cells were 13 
processed as previously described [42]. Briefly, paraformaldehyde-fixed samples were incubated in 14 
70% (v/v) ethanol at 4 °C overnight,  rehydrated in PBS for 30 min, and permeabilized in PBS 0.4% 15 
Triton X-100, 0.05% CHAPS for 10 min at room temperature. Before the in situ hybridization step, 16 
samples were pre-treated with hybridization buffer (10% formamide, 2X SSC buffer, 0.2 mg mL−1 E. coli 17 
522 tRNAs, 0.2 mg mL−1 sheared salmon sperm DNA, and 2 mg mL−1 BSA) and then incubated overnight 18 
with 50 ng of an EBNA1-digoxigenin DNA probe (5′-CTTTCCAAACCACCCTCCTTTTTTGCGCCT-19 
GCCTCCATCAAAAA-digoxigenin-3′) in a humidified chamber at 37 °C. To avoid secondary structure 20 
formation, the probe was diluted in 5 µL of water, denatured at 80 °C for 5 min, chilled on ice for 5 21 
min, and then re-suspended in 35 µL of hybridization buffer. After hybridization, samples were serially 22 
washed for 20 min with 2X SSC buffer, 10% formamide, hybridization buffer (twice), 2X SSC buffer, and 23 
PBS. Samples were then saturated with PBS 3% BSA for 30 min and incubated for 2 h at room 24 
temperature with a mix of primary antibodies containing the mouse anti-digoxigenin (clone DI-22, 25 
Sigma, 1:200) and the rabbit anti-nucleolin (ab22758, Abcam, 1:1,000). Subsequently, PLA was carried 26 
out using the anti-rabbit plus and anti-mouse minus Duolink probes (Sigma) and the Duolink FarRed 27 
PLA in situ kit (Sigma) following the manufacturer’s protocol. Experiments were performed in duplicate 28 
and 100 cells per sample and per replicate were imaged and analyzed. 29 
5.4.5. RNA pull-down assay 30 
These experiments were performed as previously described [22,51]. Briefly, recombinant NCL (kind ly 31 
provided by Prof. Weinhold, Aachen, Germany) was used for pulldown assays with the following RNA 32 
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oligonucleotides: g4-EBNA1 (5′-GGGGCAGGAGCAGGAGGA-3′-TEG-Biotin) or GM (5′-GAGGCAGUAG-1 
CAGUAGAA-3′-TEG-Biotin, not able to form G4 according to the GQRS-H software). To allow the 2 
formation of the G4, the oligonucleotides were resuspended in the folding buffer (10 mM Tris-HCl pH 3 
7.5, 100 mM KCl, 0.1 mM EDTA;), heated at 95 °C for 5 min, and then slowly and progressively cooled 4 
down to 4 °C (cooling rate of 2 °C min−1) using a Veriti thermal cycler (Applied BioSsystems). To avoid 5 
unspecific binding, high-affinity streptavidin sepharose beads (GE Healthcare) were incubated in 1 mL 6 
blocking buffer containing (10 mM Tris-HCl pH 7.5, 100 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.01% Triton 7 
X-100,  0.1% BSA, 0.02% S. cerevisiae tRNAs) for 1 h at 4 °C on a rotating wheel. A 10-pg amount of 8 
folded biotinylated RNA oligonucleotide was incubated with 50 µL of suspension containing the 9 
streptavidin-coupled sepharose beads for 90 min at 4 °C on a rotating wheel. Then, 200 ng of 10 
recombinant NCL was incubated with the RNA oligonucleotides bound to the beads during 90 min at 11 
room temperature. Beads were washed with increasing KCl concentration (200 to 800 mM). Protein 12 
still bound to beads after the washes were eluted using 2X SDS loading buffer and analyzed by western 13 
blotting against NCL, as previously described. In the input lane of the western blots was loaded a 14 
quantity of recombinant NCL protein which corresponds to half of the quantity that was incubated 15 
with the beads for each condition. 16 
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